TH 29 ANNUAL SYMPOSIUM OF THE
INTERNATIONAL CANNABINOID RESEARCH SOCIETY
BETHESDA
MARYLAND, USA
JUNE 29 – JULY 4, 2019
TH 29 ANNUAL
SYMPOSIUM OF THE
INTERNATIONAL CANNABINOID RESEARCH SOCIETY
BETHESDA
JUNE 29 – JULY 4 , 2019
Symposium Programming by Cortical Systematics LLC
Copyright © 2019
International Cannabinoid Research Society Research Triangle Park, NC USA
ISBN: 978-604-0-00050-7
These abstracts may be cited in the scientific literature as follows:
Author(s), Abstract Title (2019) 29th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #.
Funding for this conference was made possible in part by grant 2R13DA016280 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
ICRS Sponsors
Government Sponsors
National Institute on Drug Abuse
Non- Profit Organization Sponsors
Kang Tsou Memorial Fund
Monique C . and George L. Braude Memorial Foundation
2019 ICRS Symposium on the Cannabinoids
Conference Coordinators
Steve Alexander, Ph.D. Heather Bradshaw, PhD. Melanie Kelly, Ph.D. Pal Pacher, M.D., Ph.D. Jason Schechter, Ph.D. Sara Whynot
Programme Committee
Mary Abood, Ph.D. Tamas Biro, M.D., Ph.D. Heather Bradshaw, Ph.D. Resat Cinar, Ph.D. David Finn, Ph.D. Jürg Gertsch, Ph.D. Grzegorz Godlewsky, Ph.D. Uwe Grether, Ph.D. Matt Hill, Ph.D. Cecilia Hillard, Ph.D. Andrea Hohmann, Ph.D. Tony Jourdan, Ph.D. George Kunos, M.D., Ph.D. Aron Lichtman, Ph.D. Alessia Ligresti, Ph.D. David Lovinger, Ph.D. Ken Mackie, M.D. Mauro Maccarrone, Ph.D. John McPartland, D.O. Pal Pacher, M.D., Ph.D. Sachin Patel M.D., Ph.D. Julian Romero, Ph.D. Ethan Russo, M.D. Anna- Maria Szczesniak, Ph.D. Katarzyna Starowicz, Ph.D. Sabine Steffens, Ph.D. Yossi Tam, D . M . D . , Ph.D. Mario van der Stelt, Ph.D. Jenny Wilkerson, Ph.D.
Lifetime Achievement Award Committee
Mary Abood, Ph.D. Rebecca Craft, Ph.D. Melanie Kelly, Ph.D. Aron Lichtman, Ph.D.
William Devane Young Investigator Award Committee
Allyn Howlett, Ph.D. Cecilia Hillard, Ph.D. Lumír Hanuš, Ph.D., D.Sc., Dr.h.c.mult.
Student Prizes Committee Chair
Steve Alexander, Ph.D.
Mechoulam Award Committee
Mary Abood, Ph.D. Francis Barth, Ph.D. Benjamin Cravatt, Ph.D. Vincenzo Di Marzo, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. John Huffman, Ph.D. George Kunos, M.D., Ph.D. Gerard Le Fur, Ph.D. Aron Lichtman, Ph.D. Beat Lutz, Ph.D. Ken Mackie, M.D. Mauro Maccarrone, Ph.D. Alex Makriyannis, Ph.D. Roger Pertwee, M.A., D.Phil, D.Sc., HonFBPhS Daniele Piomelli, Ph.D. Patti Reggio, Ph.D. Murielle Rinaldi- Carmona, Ph.D. ANDREAS ZIMMER, PH.D.
2019 ICRS Board of Directors
Executive Director Melanie Kelly, Ph.D.
President Pal Pacher, M.D., Ph.D.
President- Elect Dave Finn, Ph.D.
Past President Heather Bradshaw, Ph.D.
Secretary Rebecca Craft, Ph.D.
Treasurer Steve Kinsey, Ph.D.
International Secretary Roger Pertwee, M.A ., D.Phil, D.Sc., HonFBPhS
Student Representative Haley Vecchiarelli, B.A.,M.Sc.
Grant PI Sachin Patel, M.D., Ph.D.
Managing Director Jason Schechter, Ph.D.
Registration: June 29th, 2019 (16.00 – 18.00)
MARRIOTT NORTH CONFERENCE CENTER BETHESDA, MD USA
Welcome Reception: 18.30 – 20.00
Day 1 th Sunday, June 30
7.30 Breakfast
8.30 Welcome and Opening Remarks
Oral Session 1. Cannabis Compounds, Genetics, chemovars and Extraction Methods
CHAIRS: JANA HAJSLOVA AND JOHN MCPARTLAND
RENAMING DINOSAURS: John M. McPartland* 8.45 EXHUMING THE ANCESTORS 1 and Geoffrey W. Guy OF “SATIVA” AND “INDICA”
SHORT- AND LONG-TERM ACUTE Carrie Cuttler*, EFFECTS OF CANNABIS ON 9.00 Alexander Spradlin HEADACHE AND MIGRAINE: 2 and Rebecca Craft A NATURALISTIC STUDY OF MEDICAL CANNABIS USERS
Lipin Ji, Yingpeng Liu, Fei Tong, Marsha Eno, Shalley Kudalkar, Alex Straiker, Ai-ling Li, Othman Benchama, Chandrashekhar Honrao, Anisha Korde, Amey Dhopeshwarkar, Paula CHIRAL Morales, Shu Xu, Michaela 9.15 Dvorakova, Dow Hurst, ENDOCANNABINOID 3 Simiao Wu, JodiAnne T. LIGANDS Wood, Nikolai Zvonok, Patricia Reggio, Ken Mackie, Lawrence Marnett, Andrea G. Hohmann, Alexandros Makriyannis and Spyros P. Nikas*
L. Cinnamon Bidwell*, Jarrod Ellingson, ACUTE SELF-ADMINISTRATION Sophie YorkWilliams, OF LEGAL MARKET FLOWER AND Hollis Karoly, Leah N. CONCENTRATED CANNABIS: 9.30 Hitchcock, Cristina 4 CANNABINOID BLOOD LEVELS, Sempio, Jost Klawitter, SUBJECTIVE INTOXICATION, AND Brian Tracy, NEUROBEHAVIORAL OUTCOMES Angela D. Bryan and Kent E. Hutchison
Jana Hajslova*, Marie Fenclova, Frantisek ASSESSING TRENDS OF CBD OILS 9.45 5 Benes, Ethan Russo QUALITY AT THE EU MARKET and Pavel Kubu
10.00 Coffee Break
Oral Session 2. Cannabidiol
CHAIRS: MICHELLE GLASS AND SAOIRSE O’SULLIVAN
Salahaden R. Sultan, ACUTE AND CHRONIC Timothy J. England EFFECTS OF CANNABIDIOL 10.30 6 and Saoirse E. ON HAEMODYNAMICS IN O`Sullivan* HEALTHY MALES
Staci A. Gruber*, Ashley M. Lambros, HIGH ANXIETY? EXAMINING Rosemary T. Smith, THE IMPACT OF FOUR WEEKS OF 10.45 M. Kathryn Dahlgren, 7 TREATMENT WITH A NOVEL HIGH Kelly A. Sagar, CANNABIDIOL PRODUCT David P. Olson and Scott E. Lukas
Tory Spindle*, Edward ACUTE PHARMACOKINETICS AND Cone, John Mitchell, PHARMACODYNAMICS OF ORAL 11.00 George Bigelow, 8 AND VAPORIZED CANNABIDIOL Ron Flegel IN HEALTHY ADULTS and Ryan Vandrey
CANNABIDIOL ATTENUATES Ewa Galaj*, COCAINE REWARD BY CB2, 5-HT 11.15 Guo-Hua Bi 1A 9 AND TRPV1 RECEPTOR and Zheng-Xiong Xi MECHANISMS IN RATS
Plenary Speaker
US CANNABIS POLICY: IMPLICATIONS FOR PUBLIC HEALTH 11.30 - 12.30 Susan R. B. Weiss, Ph.D.
Director Division of Extramural Research National Institute on Drug Abuse, Bethesda, MD, USA
12.30 Lunch
NIDA Student Training Session
12.30 OVERVIEW OF NIH/NIDA RESEARCH TRAINING AND GRANT OPPORTUNITIES IN CANNABINOID RESEARCH
BETH BABECKI, WOODY LIN AND RAO RAPAKA
ICRS Lifetime Achievement Award
CANNABINOID PHARMACOLOGY: MY FIRST HALF CENTURY 13.30 - 14.30 Roger Pertwee, M.A., D.Phil, D.Sc., HonFBPhS
Institute of Medical Sciences University of Aberdeen, Scotland
Oral Session 3. CB1 Pharmacology
CHAIRS: RESAT CINAR AND YOSSI TAM
Thuy Nguyen, Ann M. Decker, Thomas F. Gamage, Jun-Xu Li, ALLOSTERIC MODULATORS 14.30 Jenny L. Wiley, OF THE CANNABINOID CB1 10 Brian F. Thomas, RECEPTOR: DIARYL UREAS Terry P. Kenakin and Yanan Zhang*
STRUCTURAL ANALYSIS OF THE Allyn C Howlett*, CB1 CANNABINOID RECEPTOR 14.45 William T. Booth 11 INTERACTING PROTEIN 1A and W. Todd Lowther (CRIP1A)
Adi Drori*, Asaad CANNABINOID-1 RECEPTOR Gamal, Shahar Azar, REGULATES SOLUBLE LEPTIN Liad Hinden, Rivka RECEPTOR LEVELS VIA C/EBP 15.00 Hadar, Daniel Wesley, HOMOLOGOUS PROTEIN (CHOP), 12 Alina Nemirovski, CONTRIBUTING TO OBESITY- Maayan Salton, Boaz RELATED HEPATIC LEPTIN Tirosh and Joseph Tam RESISTANCE
Resat Cinar*, Nathan J. Coffey, Steven P. MRI-1867, A THIRD GENERATION Bodine, Joshua K. CB1R ANTAGONIST, Park, Malliga R Iyer, FOR EFFECTIVE THERAPY 15.15 Bernadette R. OF A RARE DISEASE, 13 Gochuico, William A. HERMANSKY-PUDLAK Gahl, May Christine V. SYNDROME PULMONARY Malicdan FIBROSIS and George Kunos
Michaela Dvorakova, A CRITICAL EVALUATION Wesley Corey, OF TERPENOID SIGNALING AT 15.30 Anaelle Zimmowitch, 14 CANNABINOID CB1 RECEPTORS Alex Straiker* IN A NEURONAL MODEL and Ken Mackie
Tania Muller, Julia Leemput, Chloé Buch, HYBRID INHIBITOR OF Laurent Demizieux, PERIPHERAL CANNABINOID-1 Patricia Passilly- RECEPTOR AND INDUCIBLE 15.45 Degrace, Resat Cinar, 15 NITRIC OXIDE SYNTHASE Malliga R Iyer, George MITIGATES THE DEVELOPMENT Kunos, Bruno Vergès, OF DYSLIPIDEMIA Pascal Degrace and Tony Jourdan*
Poster Session 1 16.00 – 18.00 P1 Reception
Notes: Presenting Author*
Day 2 Monday, July 1st
7.30 Breakfast
8.30 Opening Remarks
Oral Session 4. CB2 Pharmacology
CHAIRS: UWE GRETHER AND MELANIE KELLY
U. Grether*, K. Atz, B. Brennecke, E. M. Carreira, C. Davies, J. Fingerle, T. Gazzi, J. Gertsch, W. Guba, A. Kimbara, C. Korn, M. Maccarrone, H. Mandhair, R. E. Martin, A. Mason, T. Miljus, M. FLUORESCENTLY LABELED Nazare, M. Nettekoven, TYPE-2 CANNABINOID RECEPTOR 8.45 S. Oddi, P. Pacher, A. (CB2R) LIGANDS: FROM INITIAL 16 Pavlovic, A. Pedrina- ATTEMPTS TOWARD A HIGHLY McCarthy, P. Pfaff, C. VERSATILE CHEMICAL TOOLBOX Raposo, M. Rogers- Evans, E. Roome, S. Röver, A. Rufer, R. Sarott, M. Soethoudt, C. Ullmer, M. van der Stelt, D. Sykes, Z. Varga, D. B. Veprintsev, M. Weise and M. Westphal
M. Nazare*, T. Gazzi, B. Brennecke, M. Weise U. Grether, K. Atz, E. M. Carreira, J. Fingerle, J. Gertsch, W. Guba, C. Korn, M. Maccarrone, H. Mandhair, T. Miljus, S. CB2 RECEPTOR DETECTION 9.00 Oddi, P. Pacher, A. BY NEW FLUORESCENTLY 17 Pavlovic, P. Pfaff, C. LABELED SYNTHETIC LIGANDS Raposo, A. Rufer, R. Sarott, C. Ullmer, M. van der Stelt, D. Sykes, Z. Varga, D. B. Veprintsev and M. Westphal
Zoltan V. Varga*, Katalin Erdelyi, Uwe Grether, Eszter Trojnar, Catarina Raposo, Jürgen Fingerle, Christoph CANNABINOID 2 RECEPTOR Ullmer, Ozge Gunduz- (CB2) EXPRESSION REVISITED: 9.15 Cinar, Michelle Glass, 18 Bela Szabo, Miklos DETECTION OF CB2 mRNA WITH Palkovits, Andrew NEW SENSITIVE TOOLS Holmes, Jürg Gertsch, Julian Romero, Cecilia Hillard and Pal Pacher
Tomohiro Kimura, Alexei Yeliseev, Mihaela Mihailescu, Diane L. 2-AG LOCATION, STRUCTURE Lynch, Walter E. Teague AND DYNAMICS IN MEMBRANES 9.30 Jr., Kirk G. Hines, 19 Lioudmila Zoubak, AND ITS INTERACTION WITH Alan Grossfield, CB2 RECEPTORS Patricia H. Reggio and Klaus Gawrisch*
Jakub Mlost*, Marta Bryk, CB2 BIASED AGONISTS AND 9.45 Magdalena Kostrzewa THEIR THERAPEUTIC POTENTIAL 20 and Katarzyna IN OSTEOARTHRITIS Starowicz
10.00 Coffee Break
Oral Session 5. Cannabinoids and Reward
CHAIRS: DAVID FINN AND STEPHANIE LAKE
Chloe J. Jordan*, DISSECTING THE REWARDING Bree Humburg, Yi He, VS. AVERSIVE EFFECTS OF Xiao Han, Guo-hua Bi, CANNABINOIDS: FINDINGS 10.30 FROM OPTOGENETIC BRAIN- 21 Eliot Gardner, STIMULATION REWARD Xiang-qun Xie MAINTAINED BY ACTIVATION and Zheng-Xiong Xi OF VTA DOPAMINE NEURONS
ENDOGENOUS CANNABINOIDS 10.45 Joseph F. Cheer* 22 AND REWARD PREDICTION
GABAPENTIN ATTENUATES Matthew L. Eckard* 11.00 SOMATIC SIGNS OF Δ9-THC 23 and Steven G. Kinsey WITHDRAWAL IN MICE
Stephanie Lake*, FREQUENT CANNABIS USE IS Thomas Kerr, Jane ASSOCIATED WITH LOWER LIKELIHOOD OF FREQUENT ILLICIT 11.15 Buxton, Zach Walsh, OPIOID USE AMONG PEOPLE WHO 24 Kanna Hayashi, Evan USE DRUGS WITH CHRONIC PAIN: Wood and M-J Milloy A LONGITUDINAL ANALYSIS
Plenary Speaker
THE NEUROBIOLOGY OF DRUG ADDICTION: FROM DRUG REWARD TO HYPERKATIFEIA 11.30 - 12.30 TO NEGATIVE REINFORCEMENT
George Koob, Ph.D.
Director National Institute on Alcohol Abuse and Alcoholism
12.30 Lunch
ICRS Young Investigator Award
ANANDAMIDE, FAAH, STRESS AND ANXIETY: A TRANSLATIONAL JOURNEY 13.30 - 14.00 Matt Hill, Ph.D.
Associate Professor The Hotchkiss Brain Institute University of Calgary, Alberta, Canada
Oral Session 6. Clinical Studies
CHAIRS: NALIN PAYAKACHAT AND ETHAN RUSSO
EFFICACY AND SAFETY OF THX-110, A PROPRIETARY Adi Zuloff-Shani*, THERAPEUTIC 14.00 Ephraim Brener COMBINATION OF Δ9- 25 and Ascher Shmulewitz TETRAHYDROCANNABINOL AND PALMITOYLETHANOLAMIDE
DOES CANNABIS HELP Nalin Payakachat*, IMPROVE INSOMNIA Ryan Vandrey, William E. 14.15 AMONG PATIENTS WITH 26 Fantegrossi, Lauren Russell POSTTRAUMATIC STRESS and Marcel O. Bonn-Miller DISORDER?
ACUTE EFFECTS OF HIGH Carrie Cuttler*, Emily 14.30 POTENCY CANNABIS ON 27 LaFrance and Aria Petrucci EVERYDAY LIFE MEMORY
Bitya Raphael*, Natalya Kogan, Malka Attar-Namdar, Mukesh HISTONE H4 ENCODES AN Chourasia, Maria G. Cascio, ENDOGENOUS PEPTIDE Avital Shurki, Joseph Tam, 14.45 THAT SIGNALS VIA THE 28 Moshe Neuman, Joseph Foldes, Roger G. Pertwee, CB2 CANNABINOID Andreas Zimmer, Itai Bab RECEPTOR and Yankel Gabet
Mark A. Ware*, Antonio Vigano, THE QUEBEC CANNABIS Pierre Beaulieu, Andrée Néron, REGISTRY, A DATABASE Yola Moride, Michelle Canac- ON THE USE OF 15.00 29 Marquis, Maja Kalaba, Marc O. CANNABIS FOR MEDICAL Martel, Jordi Perez, Julie PURPOSES: Desroches and William Barakett FINAL RESULTS
A CONTROLLED Marcel O. Bonn-Miller*, PROSPECTIVE Megan Brunstetter , OBSERVATIONAL STUDY 15.15 Alexandra Simonian, OF THE LONGITUDINAL 30 Hal Wortzel ASSOCIATIONS BETWEEN and Ryan Vandrey CANNABIS USE AND PTSD SYMPTOMATOLOGY
A RANDOMIZED TRIAL Dylan Zylla*, Justin Eklund, OF MEDICAL CANNABIS Grace Gilmore, Alissa IN PATIENTS WITH Gavenda, Gabriella ADVANCED CANCERS VazquezBenitez, Pamala 15.30 TO ASSESS IMPACT 31 Pawloski, Tom Arneson, ON OPIOID USE Angela Birnbaum, Stephen AND CANCER-RELATED Dahmer, Matthew Tracy SYMPTOMS: A PILOT AND and Arkadiusz Dudek FEASIBILITY STUDY
Joshua Rein*, Lindsay Texter, Mark Wurfel, Edward Siew, MARIJUANA USE AND Amit Garg, Thida Tan, Paul 15.45 KIDNEY OUTCOMES IN 32 Kimmel, James Kaufman, THE ASSESS-AKI COHORT Vernon Chinchilli and Steven Coca
Poster Session 2 16.00 – 18.00 P2 Reception
18.00 Business Meeting
Notes: Presenting Author*
Day 3 Tuesday, July 2nd
7.30 Breakfast
8.30 Opening Remarks
Oral Session 7. Development, Reproductive Function, Smell and Cancer
CHAIRS: ANNA KALINOVSKY AND JULIAN ROMERO
Kylie Black, Shawyon CANNABINOID Baygani, Ricardo Martinez, SIGNALING REGULATES 8.45 Tristen Mier, Alexandria Bell, 33 CEREBELLAR Ken Mackie DEVELOPMENT and Anna Kalinovsky*
BEHAVIOURAL AND COGNITIVE Shahnaza Hamidullah*, EFFECTS OF 9.00 Claudia D. Lutelmowskij ADOLESCENT 34 and Jibran Y. Khokhar CANNABIS AND ALCOHOL CO-USE IN ADULTHOOD
MICE MISSING CNR1 Xiaofei Sun*, Yingju Li, AND CNR2 SHOW 9.15 Fenghua Bian 35 IMPLANTATION and Sudhansu K. Dey DEFECTS
NON-PSYCHOTROPIC CANNABINOIDS SUPPRESS TUMOR Ali Mokhtar Mahmoud*, GROWTH BY ACTING Viviana Marolda, Magdalena ON METABOLIC 9.30 Kostrzewa, Vincenzo Di 36 REPROGRAMMING AND Marzo, Roberto Ronca ONCOGENIC PATHWAYS and Alessia Ligresti IN HORMONE REFRACTORY PROSTATE CANCER
CANNABINOID RECEPTOR-MEDIATED Huizhi Du, Maya Ploss, MODULATION OF 9.45 Alex Straiker 37 INTERNEURONS IN THE and Thomas Heinbockel* MAIN OLFACTORY BULB
10.00 Coffee Break
10.30 In Memoriam
Oral Session 8. Pain, Stress, Sleep and Psychiatric Disorders
CHAIRS: ANDREA HOHMANN AND DAVE LOVINGER
ENDOCANNABINOID ROLES IN SLEEP David M Lovinger*, Karina P 10.45 STABILITY AND SLEEP 38 Abrahao and Matthew J Pava DISRUPTION BY CANNABINOID DRUGS
CP55,940 Madhusudhanan Narasimhan*, ANTINOCICEPTIVE Henry Blanton, Jennifer EFFECT, DEVELOPMENT Brelsfoard, Diana E. OF TOLERANCE AND 11.00 Sepulveda, Angela N. ACTIVATION OF JNK 39 Henderson-Redmond, SIGNALING IN THE Daniel J. Morgan CISPLATIN-INDUCED and Josée Guindon NEUROPATHIC PAIN MODEL
MOLECULAR AND PHARMACLOGICAL EVIDENCE FOR THE SODIUM-CALCIUM EXCHANGER-1 (mNCX-1) Douglas E. Brenneman*, AS A MEDIATOR OF 11.15 William A. Kinney 40 CBD- AND KLS-13019- and Sara Jane Ward APPLIED PROTECTION AGAINST PACLITAXEL- INDUCED TOXICITY IN DORSAL ROOT GANGLION CULTURES
NOVEL NEGATIVE ALLOSTERIC Catharine A. Mielnik*, MODULATOR (NAM) Chun Kit Li, Iain R. Greig, OF CANNABINOID Mostafa H. Abdelrahman, RECEPTOR 1 (CB1) Laurent A. Trembleau, 11.30 AMELIORATES 41 WM Burnham, SYMPTOMS DUE Ali Salahpour, TO DOPAMINE Amy J. Ramsey DYSREGULATION and Ruth A. Ross IN PSYCHIATRIC DISORDERS
THE DIFFERENTIAL ROLE OF Giulia Donvito*, DIACYLGLYCEROL Ryan Mischel, LIPASES IN REVERSING Virginia McLane, Daisuke MECHANICAL 11.45 Ogasawara, Hamid Akbarali, 42 SENSITIVITY IN A Ku-Lung Hsu, MOUSE MODEL OF Benjamin F Cravatt CHEMOTHERAPY- and Aron H Lichtman INDUCED PERIPHERAL NEUROPATHY (CIPN)
Kang Tsou Memorial Lecture
VEGAS AND ULTRA-LSD: NEW CHEMICAL AND SYNTHETIC BIOLOGICAL TECHNOLOGIES
12.00 – 13.00
Bryan Roth, M.D., Ph.D.
Director, NIMH Psychoactive Drug Screening Program Distinguished Professor, Department Of Pharmacology UNC Chapel Hill , NC
13.00 Lunch
13.00 Industry Breakouts
NIDA Networking Session
CANNABINOID RESEARCH FINDINGS AND FUTURE RESEARCH DIRECTIONS
Chair: Steven Gust, Director, International Program
Division of Neuroscience and Behavior
BASIC RESEARCH OPPORTUNITIES AND PRIORITIES RELATED TO THE CANNABINOIDS
Rita J. Valentino, Division Director
BASIC RESEARCH ON CANNABINOIDS IN DNBR
Roger Sorensen, Chief, Integrative Neuroscience Branch
Division of Therapeutics and Medical Consequences
DEVELOPING CANNABIS-BASED MEDICATIONS, HOW CAN NIDA’S DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES HELP?
14.00 – 16.00 Robert Walsh, Chief, Regulatory Affairs Branch
SUPPORTING CANNABIS RESEARCH IN NIDA’S DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES
Aidan Hampson, Clinical Research Grants Branch
Division of Epidemiology, Services and Prevention Research
NIDA’S CANNABIS POLICY RESEARCH PORTFOLIO: CURRENT AND FUTURE DIRECTIONS
Marsha F. Lopez, Chief, Epidemiology Research Branch
NIDA’S RESEARCH INTERESTS IN THE PREVENTION OF CANNABIS MISUSE
Amy Goldstein, Chief, Prevention Research Branch
NIDA Intramural Research Program
CANNABIS-BASED MEDICATION DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE USE DISORDERS
Zheng-Xiong Xi, Chief, Addiction Biology Unit
COCAINE-INDUCED ENDOCANNABINOID RELEASE MEDIATED BY EXTRACELLULAR VESICLES IN THE VENTRAL TEGMENTAL AREA
Carl Lupica, Chief, Electrophysiology Research Section
Day 4 rd Wednesday, July 3
7.30 Breakfast
8.30 Opening Remarks
Oral Session 9. Immune Function, Neurodegenerative and Cardiovascular Disorders
CHAIRS: IRENE BENITO-CUESTA AND SABINE STEFFENS
Ines Reynoso- NEW STRATEGIES TARGETING Moreno*, Silvia Tiezt, THE ENDOCANNABINOID SYSTEM 8.45 Britta Engelhardt, TO ATTENUATE DISEASE 43 Jürg Gertsch PROGRESSION IN A MOUSE and Andrea Chicca MODEL OF MULTIPLE SCLEROSIS
Douglas J. Hermes*, Changqing Xu, Rick B. Meeker, Micah J. Niphakis, Benjamin F. GPR18 MEDIATES MICROGLIAL 9.00 Cravatt, Ken Mackie, NEUROTOXICITY INDUCED BY 44 Aron H. Lichtman, HIV-1 TAT PROTEIN IN VITRO Bogna M. Ignatowska- Jankowska and Sylvia Fitting
Kevin S. Murnane*, Lindsey Phillips- Lindsey, Cedrick M. β-CARYOPHYLLENE IMPROVES Daphney, MEMORY FUNCTION 9.15 Aboagyewaah AND DECREASES KEY 45 Oppong-Damoah, INFLAMMATORY CYTOKINES Richard D. Khusial, IN AGED MICE Ayman Akil and Peter N. Uchakin
Irene Benito-Cuesta*, Samuel Ruiz de Martín Esteban, Ana M. THE ROLE OF MICROGLIAL CB2 Martínez Relimpio, M. RECEPTORS IN BETA AMYLOID 9.30 Asunción Barreda- 46 PHAGOCYTOSIS: IN VITRO AND Manso, Rosa M. IN VIVO STUDIES Tolón, Cecilia J. Hillard, Julián Romero and M. Teresa Grande
Janos Paloczi*, Csaba Matyas, Zoltan V. ALCOHOL BINGE-INDUCED Varga, Resat Cinar, CARDIOVASCULAR 9.45 György Hasko, DYSFUNCTION INVOLVES 47 Thomas H. Schindler, ENDOCANNABINOID-CB1-R George Kunos SIGNALING and Pal Pacher
10.00 Coffee Break
Oral Session 10. Endogenous Signaling Systems
CHAIRS: LINDA PARKER AND MARIO VAN DER STELT
Ephraim Brener*, PALMITOYLETHANOLAMIDE 10.30 Adi Zuloff-Shani and MODULATES CB1 AFFINITY 48 Ascher Shmulewitz TO THC
Sergiy Tyukhtenko*, Xiaoyu Ma, Kiran MONOACYLGLYCEROL LIPASE Vemuri, Spyros Nikas, 10.45 INHIBITION: BIOPHYSICAL AND 49 Michael Malamas MECHANISTIC INSIGHTS and Alexandros Makriyannis
ELEVATED LEVELS OF ARACHIDONIC ACID-DERIVED LIPIDS, INCLUDING Emma Leishman*, PROSTAGLANDINS AND 11.00 Ken Mackie and ENDOCANNABINOIDS, ARE 50 Heather B Bradshaw PRESENT THROUGHOUT ABHD12 KO BRAINS: NOVEL INSIGHTS INTO THE NEURODEGENERATIVE PHENOTYPE
Josephine Watson, METABOLISM OF Lauren Carnevale, ENDOCANNABINOIDS AND 11.15 William Arnold, PHYTOCANNABINOIDS BY 51 Austin Weigle CYTOCHROME P450 TO PRODUCE and Aditi Das* NOVEL BIOACTIVE METABOLITES
Caroline Turcotte, Anne-Sophie ENDOCANNABINOID Archambault, HYDROLYSIS INHIBITION Élizabeth Dumais, UNRAVELS THAT UNSATURATED Cyril Martin, Marie- FATTY ACIDS INDUCE A ROBUST 11.30 Renée Blanchet, 52 SYNTHESIS OF Elyse Bissonnette, ENDOCANNABINOID-GLYCEROLS Alain Veilleux, IN HUMAN MYELOID Michel Laviolette, LEUKOCYTES Vincenzo Di Marzo and Nicolas Flamand*
Linda A. Parker*, Gavin N. Petrie, Kiri L.Wills, Fabiana Piscitelli, Reem Smoum , Cheryl L. Limebeer, Erin M. OLEOYL GLYCINE INTERFERES Rock, Samantha WITH ACUTE NALOXONE- Ayoub, Ashlyn 11.45 PRECIPITATED MORPHINE 53 Humphrey, Alexia WITHDRAWAL, BUT NOT Gene, Madeleine MORPHINE REWARD Sheppard-Perkins, Marieka DeVuono, Aron H. Lichtman, Vincenzo Di Marzo and Raphael Mechoulam
12.00 Lunch
12.30 Industry Breakouts
Oral Session 11. Wound Healing, Microbiota and Obesity
CHAIRS: ADI DRORI AND MITZI NAGARKATTI
Natalia Murataeva*, A CENTRAL ROLE FOR Emma Leishman, 13.30 2-OLEOYLGLYCEROL IN 54 Heather Bradshaw CORNEAL WOUND HEALING and Alex Straiker
Sam R C Johnson*, James J Burston, Victoria J Tyrrell, Maceler Aldrovandi, 12/15 LIPOXYGENASE Rossa Inglis, Robert ORCHESTRATES CELLULAR 13.45 55 Andrews, Jenna Cash, REMODELLING DURING Paul Martin, WOUND REPAIR Christopher P Thomas and Valerie B O'Donnell
ACTIVATION OF CANNABINOID-1 Tania Muller, Laurent RECEPTORS (CB1R) IN ADIPOSE Demizieux, Pablo TISSUE CONTRIBUTES TO 14.00 Ortega-Deballon, Tony 56 METABOLIC RISK BY INHIBITING Jourdan, Bruno Vergès FAT MOBILIZATION AND and Pascal Degrace* ALTERING INSULIN SENSITIVITY
Kathryn Miranda*, William Becker, ENDOCANNABINOID SIGNALING Brandon Busbee, MEDIATES SUSCEPTIBILITY TO 14.15 Nicholas Dopkins, HIGH FAT DIET-INDUCED 57 Yin Zhong, Prakash S. INTESTINAL DYSBIOSIS AND Nagarkatti and Mitzi REGULATES METABOLIC HEALTH Nagarkatti
Cristoforo Silvestri*, Claudia Manca, Niokhor Dione, BIDIRECTIONAL INTERACTION Sebastien Lacroix, BETWEEN THE GUT 14.30 Ulrike Taschler 58 MICROBIOME AND THE Nicolas Flamand, ENDOCANNABINOIDOME Frederic Raymond and Vincenzo Di Marzo
Amira Mohammed*, Hasan Alghetaa, THC TREATMENT IMPROVED 14.45 Marcus Kaul, Prakash NEUROTOXICITY BY ALTERING 59 Nagarkatti and Mitzi THE MICROBIOTA Nagarkatti
President’s Lecture
THE STRUCTURES AND FUNCTIONS OF THE CANNABINOID RECEPTORS
15.00 – 16.00 Alexandros Makriyannis, Ph.D.
George D. Behrakis Chair of Pharmaceutical Biotechnology Director, Center for Drug Discovery (CDD) Northeastern University, Boston, MA, USA
16.00 – 18.00 Poster Session 3 P3
18.30 Reception
ICRS BANQUET
AND 19.00
AWARDS CEREMONY
Departure: Thursday, July 4th
Notes: Presenting Author*
POSTER SESSION P1
Sunday, June 30th: 16:00 - 18:00
Johanna Baas*, Ivo Heitland, DOES ADMINISTRATION OF Renate de Bock, Minne Prüst CANNABIDIOL ENHANCE EXTINCTION P1-1 and Iris Schutte OF FEAR IN HUMANS?
Daniel Barrus*, Purvi Patel, Thuy Nguyen, Charlotte Farquhar, PHARMACOLOGICAL Tim Lefever, Yanan Zhang, CHARACTERIZATION OF THE P1-2 Jenny Wiley, Thomas Gamage SYNTHETIC CANNABINOID EG-018 and Brian Thomas
Paula Berman*, Liron Sulimani, CANNABINOIDOMICS – Anat Gelfend, Keren Amsalem, AN ANALYTICAL TOOL TO P1-3 Liran Baram, Gil Lewitus, Igal UNDERSTAND THE EFFECT OF Louria-Hayon and David Meiri MEDICAL CANNABIS TREATMENT
Stefan Brand*, Hans-Jürgen ENANTIOMERIC EXCESS Niemeyer, Carsten Röttger DETERMINATION OF SYNTHETIC P1-4 and Matthias Winkler CANNABINOIDS
Chris Breivogel*, Anicet Tresor CBD BLOCKS THE SEIZURE-INDUCING Padjio Tchuisseu P1-5 ACTIVITY OF CP55940 and Nshan Muradyan
LACK OF STANDARDIZATION IN CANNABIS VARIETY NAMES IN BOTH John Brunstein*, May Cui, Jerian GREY MARKET AND LEGAL SUPPLY P1-6 Reynolds, Kevin She and Ying Ng CHAINS IN CANADA: EVIDENCE FOR NECESSITY OF GENETIC VERIFICATION
Marta Baranowska–Kuczko*, CHRONIC CANNABIDIOL TREATMENT Hanna Kozłowska, Monika Kloza, IMPROVES VASCULAR FUNCTION OF P1-7 Olga Sadowska and Barbara HYPERTENSIVE DOCA-SALT RATS IN Malinowska VASCULAR BED SPECIFIC MANNER
CELLULAR MEMBRANE AFFINITY CHROMATOGRAPHY (CMAC) AS A TOOL Lukasz Ciesla* TO IDENTIFY PHARMACOLOGICALLY P1-8 ACTIVE COMPOUNDS INTERACTING WITH TRANSMEMBRANE PROTEINS
Nathan J. Coffey*, Bernadette R. CANNABINOID CB1R Gochuico, Joshua K. Park, RECEPTOR IS OVERACTIVATED IN Tony Jourdan, Kevin J. O’Brien, P1-9 HERMANSKY-PUDLAK SYNDROME William A. Gahl, George Kunos PULMONARY FIBROSIS and Resat Cinar
APPLICATION OF OXFORD NANOPORE John Brunstein, May Cui*, MINION PLATFORM IN CANNABIS P1-10 Jerian Reynolds and Ying Ng GENOMICS AND METAGENOMICS: FIRST IMPRESSIONS
Gregory G. Martin, Friedhelm DISCOVERY OF STEROL CARRIER Schroeder, Cecilia J. Hillard PROTEIN-2 INHIBITORS USING P1-11 and Christopher W. Cunningham* RATIONAL PROBE DESIGN
Marieka V. DeVuono*, Alexandra NAUSEA PRODUCED BY HIGH Bath, Erin M. Rock, Cheryl M. DOSE THC: ASSESSMENT OF P1-12 Limebeer and Linda A. Parker PHARMACOLOGICAL TREATMENTS
Tama Evron*, Hongfeng Deng, SELECTIVE INHIBITION OF THE Gang Sun, Alison O’Mahony, CANNABINOID RECEPTOR CB1 FOR P1-13 Xiao Feng, Mark Tepper, THE TREATMENT OF INFLAMMATION Sergei Atamas and Barbara White AND FIBROSIS
David B. Finlay*, Jamie J. CHARACTERISATION OF Manning, Christa E. Macdonald, AMB-FUBINACA: A BIASED Mikkel S. Ibsen, P1-14 AGONIST AND TOXIC SYNTHETIC Samuel D. Baniste CANNABINOID OF ABUSE and Michelle Glass
COMPOUNDING OF CANNABIS PRODUCTS WITH SPECIFIC PLANT Ryan Taché DERIVED ESSENTIAL OIL P1-15 and Constance Finley* CONSTITUENTS FOR TARGETED THERAPIES
Daniel H. Foil*, APPLYING MACHINE LEARNING Kimberley M. Zorn, Alex M. Clark TO ENDOCANNABINOID TARGETS P1-16 and Sean Ekins WITH ASSAY CENTRAL
Thomas F. Gamage*, Charlotte E. Farquhar, Daniel Barrus, Tony STRUCTURE-ACTIVITY Landavazo, Joseph Wilson, RELATIONSHIP STUDIES OF P1-17 Brian F. Thomas, Bruce E. Blough CB1 PAM 2-PHENYLINDOLE SCAFFOLD and Jenny L. Wiley
PERIPHERAL CB1 RECEPTOR Grzegorz Godlewski*, Resat BLOCKADE REDUCES VOLUNTARY Cinar, Nathan J. Coffey, Jie Liu, ALCOHOL DRINKING BY INHIBITING Tony Jourdan, Ozge Gunduz THE FORMATION OF BIOLOGICALLY Cinar, Bani Mukhopadhyay, Lee ACTIVE GHRELIN THROUGH A P1-18 Chedester, Ziyi Liu, Douglas Osei- CB1-DEPENDENT FATTY ACID Hyiaman, Malliga R. Iyer, Joshua OXIDATION IN THE STOMACH K. Park, Roy G. Smith, Hiroshi AND ITS SIGNALLING VIA GASTRIC Iwakura and George Kunos VAGAL AFFERENTS IN MICE
VARIABILITY AND PAUCITY OF Adrianne Wilson-Poe, Eric Larsen, MEDICALLY RELEVANT CANNABIS P1-19 Conan Liu and Ari Greis* PRODUCTS IN STATE REGULATED CANNABIS RETAIL DISPENSARIES
TRANSCRIPTOME-LEVEL ANALYSIS OF Michael Grider* CBD-MEDIATED NEUROPROTECTION IN P1-20 A SEROTONERGIC CELL LINE
EVALUATION OF THE RESPIRABLE Tobias Gutowski* FRACTION OF CANNABIDIOL METERED P1-21 and Regina Scherließ DOSE INHALERS
Antonei B. Csoka, EPIGENETIC ANALYSIS OF THE EFFECTS Marcus D. Sojourner P1-22 OF A SYNTHETIC CANNABINOID and Thomas Heinbockel*
CB1 MUTATIONS TO TEST THE Dow P. Hurst*, David B. Finlay, RELEVANCE OF TARANABANT Diane L. Lynch, Michelle Glass CONTACT WITH N-TERMINAL P1-23 and Patricia H Reggio RESIDUES F102 AND M103 IN CB1 CRYSTAL STRUCTURE
Sri Sujana Immadi*, Zhixing Wu, STRUCTURE-ACTIVITY RELATIONSHIP Rachel Dopart, Mohammad STUDIES OF POSITIVE ALLOSTERIC Mustafa, Giulia Donvitor, Aron H. P1-24 MODULATORS OF THE CANNABINOID Lichtman, Debra A. Kendall CB1 RECEPTOR and Dai Lu
Israa Isawi*, Paula Morales, GPR6: MODEL DEVELOPMENT, Dow Hurst, Nadine Jagerovic P1-25 DRUG DESIGN AND SYNTHESIS and Patricia Reggio
Ian R. Jacobs*, Changqing Xu, Douglas J. Hermes, Alexis League, INHIBITORY CONTROL DEFICITS Callie Xu, Micah J. Niphakis, ASSOCIATED WITH UPREGULATION OF Benjamin F. Cravatt, Ken Mackie, P1-26 CB1R IN THE HIV-1 TAT TRANSGENIC Aron H. Lichtman, Bogna M. MOUSE MODEL OF HAND Ignatowska-Jankowska and Sylvia Fitting
Kavita M. Jeerage*, Chris L. FUNDAMENTAL PARTITIONING Suiter, Elijah N. Holland, RELATIONSHIPS OF COMPOUNDS Megan E. Harries, P1-27 INDICATIVE OF CANNABIS PLANTS Jason A. Widegren OR CANNABIS EXPOSURE and Tara M. Lovestead
Bryan W Jenkins*, Tapia Foute LASTING DECREASE OF Nelong, Samantha D Creighton, CORTICOSTRIATAL COHERENCE Boyer D Winters, IN RATS AFTER ACUTE P1-28 Melissa L Perreault EXPOSURE TO VAPOURIZED and Jibran Y Khokhar ∆9-TETRAHYDROCANNABINOL
THE CB1 POSITIVE ALLOSTERIC Steven G. Kinsey*, Matthew L. MODULATOR ZCZ011 BLOCKS P1-29 Eckard and Kristen R. Trexler ∆9-THC WITHDRAWAL IN MICE
Yi William Yang, Rupali CHEMICAL COMPOSITION-ACTIVITY Vyawahare, Justin Ryk, Albert ANALYSES OF 59 MEDICAL P1-30 H.C. Wong, Hance A. Clarke CANNABIS SAMPLES: A MEDICINAL and Lakshmi P. Kotra* CHEMISTRY APPROACH
INTEGRATING CANNABIDIOL WITH MITOCHONDRIAL MODIFIERS Stefan Kuprowsky* P1-31 IN THE TREATMENT OF PTSD AND PSYCHOSIS
Luciana Leo*, Rufaida Al Zoubi, MUTATIONAL ANALYSIS REVEALS Pingwei Zhao, Daohai Yu, BIASED SIGNALING AT THE CB1 P1-32 Eugen Brailoiu, Patricia H. Reggio CANNABINOID RECEPTOR and Mary E. Abood
Dai Lu*, Zhixing Wu, Sri Sujana Immadi, Rachel Dopart, DESIGN AND SYNTHESIS OF 3-AMINO-2- Mohammad Mustafa, Giulia PHENYL INDOLE ANALOGS AS NOVEL P1-33 Donvitor, and Aron H. Lichtman, ACHIRAL LIGANDS FOR ALLOSTERIC Kristen R Trexler, Steven G. MODULATION OF THE CB1 RECEPTOR Kinsey and Debra A. Kendall
Ryan Maguire*, Ronan Lee, A META-ANALYSIS ON THE Saoirse E. O’Sullivan EFFECTS OF CANNABIDIOL IN P1-34 and Timothy J England EXPERIMENTAL STROKE
THE PHARMACOLOGICAL EFFECTS Ryan F Maguire*, Timothy J OF SYNTHETIC OR PLANT-DERIVED P1-35 England and Saoirse E O’Sullivan CANNABIDIOL (CBD) ARE SIMILAR IN A RANGE OF HUMAN CELL LINES
George Amato, Amruta Manke, Robert Wiethe, Vineetha DEVELOPMENT OF A PERIPHERALLY Vasukuttan, Rodney Snyder, RESTRICTED CB1 RECEPTOR P1-36 Yun Lan Yueh, Ann Decker, ANTAGONIST FOR ALCOHOL Scott Runyon, Nayaab Khan INDUCED LIVER DISEASE and Rangan Maitra*
DEVELOPMENT OF AN INTRAOCULAR Soumyajit Majumdar*, PRESSURE LOWERING, OPHTHALMIC Mahmoud A. ElSohly, FORMULATION CONTAINING THE Δ9- P1-37 Waseem Gul TETRAHYDROCANNABINOL (Δ9-THC) and Brian Murphy PRODRUG, Δ9-THC-VAL-HS (NB1111)
Chandrani G. Majumdar*, Suman POTENCY OF CANNABIS AND Chandra, Mohamed M. Radwan, RELATED PRODUCTS IN THE USA P1-38 James C. Church DURING THE PERIOD 2008-2018 and Mahmoud A. ElSohly
INFLUENCE OF CHRONIC CANNABIDIOL Barbara Malinowska*, Anna ADMINISTRATION ON Pędzińska-Betiuk, Marek Toczek, CARDIOVASCULAR PARAMETERS, Michał Biernacki, Magdalena ENDOCANNABINOID LEVELS P1-39 Timoszuk, Anna Jastrząb, Jolanta AND OXIDATIVE STRESS IN Weresa and Patryk Remiszewski SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS
TOXICOLOGICAL PROFILE OF Yehoshua Maor*, Lior Sinai SELECTED TERPENOIDS PRESENT IN P1-40 and Lumir Hanus CANNABIS AND IN OTHER PLANTS – FOCUS ON BETA-CARYOPHYLLENE
AN ESTIMATION OF THE CB1 RECEPTOR ANTAGONISM OF CANNABIDIOL ON Amna C. Mazeh*, James A. Angus a1-ADRENOCEPTOR-MEDIATED P1-41 and Christine E. Wright CONTRACTIONS OF RAT VASA DEFERENTIA
Ana Martín-Sánchez, Guillermo CANNABIDIOL BLOCKS THE Moreno-Sanz*, Adriana Castro- HYPO-LOCOMOTIVE EFFECT Zavala, Carlos Ferreiro-Vera, OF Δ9-THC THROUGH A P1-42 Xavier Nadal, Olga Valverde GLUTAMATERGIC/DOPAMINERGIC- and Verónica Sánchez de Medina DISCRIMINATING MECHANISM
THE PRESENCE OF CBD IN CANNABIS Raeghan L. Mueller*, FLOWER MODERATES THE Sophie L. YorkWilliams, L. RELATIONSHIP BETWEEN BLOOD Cinnamon Bidwell, Timothy P1-43 THC CONCENTRATION AND FATTY Helmuth, Angela D. Bryan ACID AMIDE HYDROLASE (FAAH) and Kent E. Hutchison GENOTYPES
IN VIVO INVESTIGATION OF THE Mohammed Mustafa*, Giulia (R)- AND (S)-STEREOISOMERS OF Donvito, Debra Kendall, Dai Lu P1-44 THE CB1 POSITIVE ALLOSTERIC and Aron H. Lichtman MODULATOR (PAM) ZCZ011
Thuy Nguyen*, Thomas Gamage, SYNTHESIS AND PHARMACOLOGICAL Ann Decker, Tiffany L. Langston, EVALUATION OF DIARYLUREA Daniel Barrus, P1-45 BASED ALLOSTERIC MODULATORS Brian F. Thomas OF CB1 RECEPTOR and Yanan Zhang
Alex Nivorozhkin* DRUG DELIVERY AND FORMULATION P1-46 and Michael Palfreyman OF CANNABINOIDS
Belén Palomares*, Martin Garrido, CHARACTERIZATION OF Claudia Gonzalo, María Gómez D9-TETRAHYDROCANNABINOLIC Cañas, Javier Fernández-Ruiz, ACID AS A DUAL PPARg/ CB1 P1-47 Giovanni Appendino, Gaetano LIGAND. IMPLICATIONS IN Morello and Eduardo Muñoz RHEUMATOID ARTHRITIS
IDENTIFICATION OF SEX, STRAIN, Cory Parks*, Byron C. Jones, AND ENTOURAGE EFFECTS IN THE Bob M. Moore II P1-48 BEHAVIORAL AND PHYSIOLOGICAL and Megan K. Mulligan RESPONSE TO CANNABINOIDS
Jimit Girish Raghav*, Kiran EVALUATING NOVEL CONTROLLED Vemuri, Spyros P. Nikas, Joseph DEACTIVATION CANNABINOID Anderson, Shashank Kulkarni, P1-49 AGONISTS WITH REDUCED TOLERANCE Torbjörn U. C. Järbe AND DEPENDENCE PROFILES and Alexandros Makriyannis
Kelly A. Sagar*, M. Kathryn Dahlgren, Rosemary T. Smith, MEDICAL CANNABIS: Ashley M. Lambros, Madeline K. AVENUE TO ALLEVIATION OR P1-50 Kuppe, Laura Patriarca PATH TO PROBLEMATIC USE? and Staci A. Gruber
Savanah L. Saldaña*, Henar Hernandez-Galante, Rachel G. Lange, Todd M. ALKALOID-BASED CB1 RECEPTOR P1-51 Stollenwerk, Andrew D. Rosicky, ALLOSTERIC MODULATORS Cecilia J. Hillard and Christopher W. Cunningham
Laura Santos*, Mario Amores, María Ceprián, Laura López- BLADDER DISFUNCTION AS A Gómez, Medardo Hernández, Vitor CONSEQUENCE ON NEONATAL P1-52 Samuel Fernandes, María Gómez- HYPOXIC-ISCHEMIC BRAIN DAMAGE: Ruiz, Ana Sofía Ribeiro PROTECTIVE ROLE OF CBD and María Ruth Pazos
Todd M. Stollenwerk*, Savanah L. CWC-1-001 EXHIBITS CB1 RECEPTOR Saldaña, Cecilia J. Hillard P1-53 ALLOSTERIC MODULATORY EFFECTS and Christopher W. Cunningham
ANTIINFLAMMATORY AND Nicole Stone*, Timothy J. England NEUROPROTECTIVE EFFECTS OF P1-54 and Saoirse E. O’Sullivan CANNABIDIOLIC ACID (CBDA) UNDER HYPOXIC CONDITIONS IN VITRO
Michael Udoh*, Marina Santiago, CANNABICHROMENE ACTIVITY AT CB1 Marika Heblinski, Iain McGregor AND CB2 RECEPTORS VIA MULTIPLE P1-55 and Mark Connor SIGNALLING PATHWAYS
THE MARIJUANA-DERIVED TERPINE Jenny L. Wilkerson*, Jasmine S. α-TERPINEOL REVERSES MECHANICAL Felix, Aron H. Lichtman ALLODYNIA AND THERMAL P1-56 and Lance R. McMahon HYPERALGESIA IN A MOUSE MODEL OF NEUROPATHIC PAIN
COMPARISON BETWEEN DRAGONFLY Lucie Foster CANNABIDIOL VS TOCRIS P1-57 and Karen Wright* CANNABIDIOL IN COLORECTAL CANCER SPHEROIDS
Zhixing Wu*, Sri Sujana Immadi, OPTIMIZED SYNTHESIS OF ZCZ011, Rachel Dopart, Kristen R. Trexler, RESOLUTION AND CHARACTERIZATION P1-58 Steven G. Kinsey, Debra A. OF ITS ENANTIOMERS Kendall and Dai Lu
Kimberley M. Zorn*, APPLYING MACHINE LEARNING TO Daniel H. Foil, Alex M. Clark CANNABINOID DRUG DISCOVERY P1-59 and Sean Ekins WITH ASSAY CENTRAL
POTENT ANTI-INFLAMMATORY EFFECTS OF CANNABIDIOL (CBD) Sandeep Kumar* TO MODULATE INDUCED P1-60 INFLAMMATION ON GINGIVAL KERATINOCYTES: IN VITRO STUDY
Notes: Presenting Author*
POSTER SESSION P2
Monday, July 1st: 16:00 - 18:00
A COMPARISON OF LIGAND-EVOKED Yousra Adel* SIGNALLING THROUGH MULTIPLE P2-1 and Steve PH Alexander PATHWAYS (CAMP, CA2+, ERK) IN CB2 RECEPTOR RECOMBINANT EXPRESSION
PREDATOR ODOR STRESS ALTERS Lucas Albrechet-Souza*, ENDOCANNABINOID SYSTEM PROTEIN Kimberly N. Whisler P2-2 EXPRESSION IN THE RAT and Nicholas W. Gilpin BASOLATERAL AMYGDALA
Jason SE Loo, Abigail L Emtage INTERPRETING THE STRUCTURES P2-3 and Steve PH Alexander* OF THE CANNABINOID RECEPTORS
THE EFFECT OF OLEOYL-GLYCINE Samantha M. Ayoub*, Cheryl L. ON REINSTATEMENT OF PREVIOUSLY Limebeer, Linda A. Parker P2-4 EXTINGUISHED MORPHINE PLACE and Raphael Mechoulam PREFERENCE IN RATS
Liran Baram*, Ella Peled, CANNABIS EXTRACTS AS Ben Yellin, Paula Berman ANTI-TUMOR AGENTS: EVIDENCE P2-5 and David Meiri FROM CANCER CELL LINES
Alexandria Bell*, LOCALIZATION OF ENDOCANNABINOID Ricardo Martinez, Kylie Black, SYNTHESIZING ENZYME NAPE-PLD P2-6 Jonah Wirt, Ken Mackie DURING CEREBELLAR DEVELOPMENT and Anna Kalinovsky
Zvi Bentwich*, CUMULATIVE EXPERIENCE FROM Timna Naftali, Naama Saban CLINICAL TRIALS IN ISRAEL: P2-7 and Lihi Barlev-Schleider REALITIES AND CHALLENGES
Kylie Black*, Shawyon Baygani, Brynna Webb, Ricardo Martinez, PERINATAL EXPOSURE TO THC Amanda Essex, Emma Leishman, P2-8 DISRUPTS CEREBELLAR DEVELOPMENT Heather Bradshaw, Ken Mackie and Anna Kalinovsky
Nicole Bowles*, Saurabh Thosar, BODY MASS INDEX BUT Maya Herzig, Noal Clemons, NOT SLEEP IMPACTS THE Garret Sauber, Alicia Stewart, ENDOGENOUS CIRCADIAN RHTYHM P2-9 Andrew McHill, Jonathan Emens, OF THE ENDOCANNABINOID Cecilia Hillard and Steven Shea ANADAMIDE IN HUMANS
Megan Sanctuary, Cinthia Wilkinson, Ashleigh Jones, CELL-SPECIFIC CB2R DEFICIENCY Brittany Murphy, Edward ATTENUATES CHRONIC INTESTINAL P2-10 Hoffenberg, Cecilia Hillard, INFLAMMATION Julian Romero and Colm Collins*
Courtney Collins*, Heather THE REALM OF Jackson, Nicolas J. Schlienz, Erin CARING OBSERVATIONAL Martin, Ryan Scalsky, Marcel O. RESEARCH REGISTRY: EVALUATING P2-11 Bonn-Miller, Joel Munson THE HEALTH IMPACTS OF and Ryan Vandrey MEDICINAL CANNABIS USE
Luis Colón-Cruz*, Agnes Acevedo-Canabal, Roberto AN UP-SCALABLE COMBINED Rodriguez-Morales, Gaurav GENETIC-BEHAVIORAL APPROACH P2-12 Varshney, Shawn Burgess, USING CB2-KO ZEBRAFISH LARVAE Guillermo Yudowski and Martine Behra
LOSS OF STRESS- AND EXERCISE- Kevin M. Crombie*, INDUCED INCREASES IN CIRCULATING Brianna N. Leitzelar, Angelique 2-ARACHIDONOYLGLYCEROL P2-13 G. Brellenthin, Cecilia J. Hillard CONCENTRATIONS IN ADULTS and Kelli F. Koltyn WITH PTSD
Mary Kathryn Dahlgren*, Atilla Gonenc, Kelly A. Sagar, IMPROVED WHITE MATTER INTEGRITY Rosemary T. Smith, Ashley M. FOLLOWING THREE AND SIX MONTHS P2-14 Lambros, Madeline K. Kuppe, OF MEDICAL CANNABIS TREATMENT Laura Patriarca and Staci A. Gruber
Andrea Tomko, Hilary Trask EFFECTS OF ATYPICAL CANNABINOIDS P2-15 and Denis J. Dupré* ON BREAST CANCER CELLS VIABILITY
TESTING CANNABINOIDS IN HUMAN Alice Domenichini, Aleksandra PANCREATIC CANCER MODELS IN Adamska, Ilaria Casari P2-16 COMBINATION WITH CURRENT and Marco Falasca* CHEMOTHERAPY AGENTS
Faiha Fareez*, Phillip Olla, THE EFFECT OF CANNABIS ON Kaitlyn Abeare, Nora McVinnie, PERFORMANCE DURING P2-17 Maurissa Hastings NEUROPSYCHOLOGICAL TESTING and Laszlo A Erdodi
HUMAN LEUKOCYTES Caroline Turcotte, Élizabeth DIFFERENTIALLY EXPRESS Dumais, Anne-Sophie ENDOCANNABINOID-GLYCEROL Archambault, Cyril Martin, LIPASES AND HYDROLYZE Marie-Renée Blanchet, Élyse P2-18 2-ARACHIDONOYL-GLYCEROL Bissonnette, Michel Laviolette, AND ITS METABOLITES FROM Vincenzo Di Marzo THE CYCLOOXYGENASE-2 AND and Nicolas Flamand* 15-LIPOXYGENASE PATHWAYS
Tamara Miljuš, Franziska M. Heydenreich, Thais Gazzi*, Atsushi Kimbara, Mark Rogers- Evans, Matthias Nettekoven, CANNABINOID RECEPTORS BIASED Arne Rufer, Christoph Ullmer, SIGNALLING – IN DEPTH PATHWAY P2-19 Wolfgang Guba, Christian Le ANALYSIS APPLYING A DIVERSE Gouill, Jürgen Fingerle, COMPOUND LIBRARY Marc Nazaré, Uwe Grether, Michel Bouvier and Dmitry B. Veprintsev
REWARDING PROPERTIES OF Rosamond M. Goodson*, HEROIN DURING ACUTE DOSING, Erica N. Golden, Leandro F. TOLERANCE, SELF-ADMINISTRATION, P2-20 Vendruscolo, George F. Koob DEPENDENCE, AND WITHDRAWAL: and Joel E. Schlosburg IMPACT OF FATTY ACID AMIDE HYDROLASE (FAAH) INACTIVATION
Zachary D.W. Dezman, David A. CANNABIS USE DISORDER AND Gorelick*, Laura Buchanan LONG-TERM POST-DISCHARGE P2-21 and Carl A. Soderstrom SURVIVAL IN TRAUMA INPATIENTS
THE EFFECTS OF Briana Hempel*, Madeline CROSS-GENERATIONAL Crissman, Mariam Melkumyan, Δ9-TETRAHYDROCANNABINOL P2-22 Chloe Winston, Jacob Madar EXPOSURE ON NICOTINE and Anthony L. Riley RESPONSIVITY IN ADULT OFFSPRING
Bogna M Ignatowska- KINEMATIC SIGNATURES OF Jankowska*, Alexander Kuck CANNABINOID SIGNALING IN MICE: P2-23 and Marylka Yoe Uusisaari CP55,940
Christos Iliopoulos-Tsoutsouvas*, Spyros P. Nikas, Shan Jiang, Wen Zhang, Simiao Wu, Nikolai NOVEL MONO AND BIFUNCTIONAL Zvonok, Jimit Girish Raghav, P2-24 CANNABINOIDS RECEPTOR PROBES Robert B. Laprairie, Joseph B. Anderson, Laura M. Bohn and Alexandros Makriyannis
Isis Janilkarn-Urena*, Kristiana THE ROLE OF THE CANNABINOID Peraza, R. Michael Little, Juanita RECEPTOR (CB R) AND SEX DURING A P2-25 Jellyman and Nancy E. Buckley MOUSE CANDIDA ALBICANS INFECTION
INVESTIGATION OF THE MECHANISM OF CANNABINOID-INDUCED CANCER Attila Keresztes* CELL SENSITIZATION AND CELL DEATH and John M Streicher P2-26 VIA THE ACTIVATION OF DR4 AND DR5
DEATH RECEPTORS IN THE LN-18 GLIOBLASTOMA CELL LINE
SMART PHONE APPLICATION FOR THE REAL-TIME ACQUISITION OF CLINICAL Debra Kimless*, Heather Denham TRIAL DATA AND REAL-TIME CAPTURE P2-27 and Stephen Goldner AND RESPONSE OF ADVERSE EFFECTS AND COMPLIANCE ASSURANCE
MARIJUANA AND CANNABINOID Rik Kline*, Robert Walsh, RESEARCH PRODUCTS AVAILABLE Steven Gust, Brian Thomas P2-28 FROM THE NATIONAL INSTITUTE and Mahmoud ElSohly ON DRUG ABUSE
ANALYSIS OF COVARIATES Alexus S. Longo ASSOCIATED WITH SELF-REPORTED P2-29 and Linda E. Klumpers* CANNABIS USE DISORDER SYMPTOMS
MEDICAL CANNABIS, PAIN AND PTSD: Lakshmi P. Kotra*, Hance A. PATIENTS-CENTRIC STUDIES IN P2-30 Clarke and Albert H.C. Wong TWO TORONTO HOSPITALS
MEDICAL CANNABIS Yi William Yang, Justin Ryk, DERIVATIVE PRODUCTS: Albert H.C. Wong, Hance A. P2-31 PRODUCT QUALITY, BIOCHEMISTRY Clarke and Lakshmi P. Kotra* AND CLINICAL RELEVANCE
Lakshmi P. Kotra*, Justin Ryk, Yi William Yang, Melissa M. POST-TRAUMATIC STRESS DISORDER Lewis-Bakker, Rupali (PTSD) AND MEDICAL CANNABIS: P2-32 Vyawahare, Ewa Wasilewski, CONNECTING 22 PATIENTS’ DATA Hance A. Clarke and Albert H.C. Wong
Lakshmi P. Kotra*, Yi William A PRAGMATIC INVESTIGATION Yang, Ewa Wasilewski, Rupali INTO MEDICAL CANNABIS P2-33 Vyawahare, Melissa M. Lewis- FOR CHRONIC PAIN Bakker and Hance A. Clarke
PHARMACEUTICAL-GRADE Albert Dahan, Tine van de Donk, CANNABIS IN CHRONIC PAIN Mikael A. Kowal*, PATIENTS WITH FIBROMYALGIA: P2-34 Marieke Niesters PHARMACOKINETIC EFFECTS and Monique van Velzen OF THREE CANNABIS VARIETIES
THE ASSOCIATION BETWEEN LOW Stephanie Lake*, Thomas Kerr, METHADONE DOSE AND EXTRA- Jane Buxton, Zach Walsh, MEDICAL OPIOID USE IS TEMPERED P2-35 Kanna Hayashi, Evan Wood BY DAILY CANNABIS USE: and M-J Milloy PRELIMINARY EVIDENCE OF A BIOLOGICAL INTERACTION
PATIENT FOCUSED INVESTIGATION OF THE ENTOURAGE EFFECT, EXPERIENCE, Mark A. Lewis* AND BENEFITS TO PUBLIC SAFETY P2-36 and Kevin Smith AND THE EMERGING THERAPEUTIC MARKETPLACE
DIRECT MEASUREMENT OF ACTIVITY- Daniel Liput*, Ao Dong, DEPENDENT ENDOCANNABINOID Kaikai He, Henry Puhl, Yulong Li MODULATION IN BRAIN SLICE USING P2-37 and David Lovinger THE NOVEL GENETICALLY-ENCODED FLUORESCENT SENSOR GRABeCB
Margaret PS Luke*, Joanna Borowska, Benjamin J. Smith, THE ABSENCE OF MONOGLYCERIDE Anna-Maria Szczesniak, Janette LIPASE (MAGL) INFLUENCES RETINAL P2-38 Nason, J. Daniel Lafreniere, FUNCTION AFTER PHOTIC INJURY Alex Straiker, François Tremblay and Melanie EM Kelly
Erin Martin*, Nicolas Schlienz, THERAPEUTIC CANNABINOIDS Joel Munson, Heather Jackson, IN ANXIETY AND DEPRESSION: P2-39 Marcel Bonn-Miller RESULTS FROM AN OBSERVATIONAL and Ryan Vandrey RESEARCH STUDY
PREVALENCE AND IMPACT OF PTSD Rhiannon Mayhugh*, Tory SYMPTOMS ON SLEEP AND CANNABIS Spindle, Marcel Bonn-Miller P2-40 ABSTINENCE IN AN URBAN CANNABIS and Ryan Vandrey TREATMENT TRIAL
WE DON'T RINSE CANNABIS: Leslie McAhren*, Lee Newman EXPOSURE AND HEALTH EFFECTS OF P2-41 and John Adgate RESIDUAL PESTICIDES IN CANNABIS
THC CONTENT AND NUMERIC Meredith Meacham*, SUBJECTIVE HIGHNESS REPORTED IN Johannes Thrul, Danielle Ramo P2-42 A REDDIT ONLINE CANNABIS and Michael Paul COMMUNITY 2010-2018
George Lockwood, Saoirse E. IN VITRO EVALUATION OF THE EFFECT OF CANNABIDIOL O’Sullivan*, Lisa C.D. Storer AS AN ADJUVANT THERAPY FOR P2-43 and Richard G. Grundy PAEDIATRIC BRAIN TUMOURS
Caitlin R. M. Oyagawa*, Braden AGONIST-INDUCED SURFACE J. Woodhouse, Michelle Glass UPREGULATION OF CANNABINOID P2-44 and Natasha L. Grimsey RECEPTOR 2 (CB2)
Shelley Paulisin*, EFFECTS OF THE CANNABINOID Hilary A. Marusak, Allesandra S. RECEPTOR 1 GENE ON FEAR P2-45 Iadipaolo, Craig Peters EXTINCTION NEURAL CIRCUITRY and Christine A. Rabinak IN HEALTHY ADULTS
PRELIMINARY RESULTS FROM Rimmerman, N*, Gale-Treister, A STUDY ON THE MOLECULAR Z, Amiaz, R, Ravona-Springer, PREDICTORS OF THE EFFICACY OF P2-46 R, Weiser M. and Yirmiya, R. ELECTROCONVULSIVE THERAPY (ECT) IN MAJOR DEPRESSION PATIENTS
Joseph Rootman*, Michelle St. SUBSTITUTING CANNABIS Pierre, Stacey Squires FOR ALCOHOL: THE IMPACT P2-47 and Zachary Walsh OF LEGALIZATION
CHRONIC USE OF Δ-9-TETRAHYDROCANNABINOL (THC) Craig Workman, John Kindred, AND CANNABIDIOL (CBD) ON Laura Ponto, John Kamholz P2-48 CEREBRAL GLUCOSE METABOLISM IN and Thorsten Rudroff* PEOPLE WITH MULTIPLE SCLEROSIS – A PILOT STUDY
ANTICANCER EFFECTS OF Khan O Saba, Dawn Boothe* CANNABINOID ON HUMAN PROSTATE P2-49 and Mansour Mahmoud CANCER CELL LINE
INPATIENT PRESCRIPTION Alexandra Sideris*, Crispiana CANNABINOID UTILIZATION RATE Cozowicz, Jashvant Poeran IN DIFFERENT SURGICAL COHORTS P2-50 and Stavros Memtsoudis IN THE UNITED STATES: A POPULATION-BASED STUDY
Rosemary Smith, M. Kathryn BLUNTING THE PAIN: EXPLORING Dahlgren, Kelly Sagar, Ashley THE IMPACT OF MEDICAL CANNABIS P2-51 Lambros*, Madeline Kuppe, TREATMENT IN PATIENTS Laura Patriarca and Staci Gruber WITH CHRONIC PAIN
Jennifer Spohrs*, Martin Ulrich, THE ENDOCANNABINOID SYSTEM AS Laura Bindila, Michael Prost, A PREDICTOR OF FEAR EXTINCTION P2-52 Paul Plener, Georg Grön LEARNING - AN FMRI STUDY and Birgit Abler
STANDARDIZATION OF CANNABIS Stacey Squires*, Sarah Daniels, DOSE FROM USER-DERIVED RATINGS; P2-53 Joseph Rootman and Zach Walsh ESTABLISHING THE INDEX OF CANNABIS EQUIVALENCE (ICE)
THE EDUCATION, KNOWLEDGE, Kevin Takakuwa*, Anthony AND PRACTICE CHARACTERISTICS Mistretta, Vanessa Pazdernik OF CANNABIS PHYSICIANS: P2-54 and Dustin Sulak A SURVEY OF THE SOCIETY OF CANNABIS CLINICIANS
DIFFERENCES AND SIMILARITIES Nehal P. Vadhan*, Diana IN RECREATIONAL AND MEDICINAL Martins-Welch and Jonathan P2-55 CANNABIS USERS IN THE NY-METRO Morgenstern AREA: A COMMUNITY SURVEY
Denise A. Valenti*, Denning MARIJUANA/CANNABIS IMPAIRED Lam, Kruti BhanuPrasad, Marc DRIVING: RETINAL DYSFUNCTION OF P2-56 Pomplun and Christopher Wu RODS, CONES AND GANGLION CELLS
A HUMAN ABUSE POTENTIAL Robert Walsh*, Nora Chiang, STUDY TO EVALUATE THE SUBJECTIVE Philip Kreiter, Katherine Bonson, AND PHYSIOLOGICAL EFFECTS OF Silvia Calderon, Michael Klein, CANNABIDIOL COMPARED TO P2-57 Debra Kelsh, Neta Nelson, DELTA-9-TETRAHYDROCANNABINOL Daniel Molina, N. Nora Yang AND ALPRAZOLAM IN and Shwe Gyaw AN INPATIENT SETTING
Daniel Wang*, Harrison Elder, IDENTIFYING AND EVALUATING Ryan Lanier, Marilyn Huestis, ABUSE-RELATED EVENTS IN CLINICAL P2-58 Nathaniel Katz TRIALS EXAMINING CANNABIS- and Jack Henningfield DERIVED SUBSTANCES
PRELIMINARY OVERVIEW OF SELF- REPORTED ADVERSE EVENTS IN Mark Ware*, Maja Kalaba, MEDICINAL CANNABIS USERS: Chris Murray P2-59 RETROSPECTIVE DATABASE ANALYSIS and Dominique Audet ACCORDING TO PRODUCT POTENCY COMPOSITION AND FORM
EFFICACY, SIDE EFFECTS, Adrianne Wilson-Poe*, AND PATTERNS OF MEDICAL Eric Larsen, Conan Liu P2-60 CANNABIS USE AMONG PATIENTS and Greis Ari WITH CHRONIC LOW BACK PAIN
DELTA-9-TETRAHYDROCANNABINOL Nicole L. Zabik*, Allesandra MODERATES THE EFFECTS OF Iadipaolo, Farrah Elrahal, Craig AVOIDANCE SYMPTOM SEVERITY P2-61 Peters, Hilary A. Marusak DURING FEAR EXTINCTION IN and Christine A. Rabinak TRAUMA-EXPOSED INDIVIDUALS
Joanna Zeiger*, CANNABINOID USE IN A POPULATION William Silvers, Ed Fleegler P2-62 BASED SURVEY OF ADULT ATHLETES and Robert Zeiger
Notes: Presenting Author*
POSTER SESSION P3
Wednesday, July 3rd: 16:00 - 18:00
Benedicte Allam-Ndoul*, Frederic Begin, Alain Houde, IMPACT OF THE Nicolas Flamand, Cristoforo ENDOCANNABINOIDOME ON SMALL P3-1 Silvestri, Vincenzo Di Marzo INTESTINE EPITHELIAL PERMEABILITY and Alain Veilleux
ROLE OF 2-ARACHIDONOYLGLYCEROL Shana M. Augustin* IN STRIATAL LONG-TERM DEPRESSION P3-2 and David M. Lovinger AND ETHANOL PREFERENCE/ DRINKING BEHAVIOR
ADAPTATIONS IN CANNABINOID Courtney A. Bouchet*, RECEPTOR SIGNALING IN THE Katherine L. Suchland VENTROLATERAL PERIAQUEDUCTAL P3-3 and Susan L. Ingram GRAY DURING PERSISTENT INFLAMMATION
James J Burston*, Sam R C Johnson, Victoria J Tyrrell, DELETION OF 12/15 LIPOXYGENASE Rossa Inglis, Robert Andrews, LEADS TO ALTERED REMODELLING P3-4 Jenna Cash, Paul Martin, DURING WOUND REPAIR Christopher P Thomas and Valerie B O'Donnell
Lawrence Carey*, Zhili Xu, TARGETING CANNABINOID Gabriela Rajic, Alexandros TYPE 2 RECEPTORS TO SUPPRESS Makriyannis, Julian Romero, P3-5 ANTIRETROVIRAL-INDUCED Cecilia Hillard, Ken Mackie NEUROPATHIC NOCICEPTION and Andrea Hohmann
THE INFLUENCE OF 2-AG ON Jakub Chwastek*, Marta Bryk CHEMOKINES EXPRESSION IN P3-6 and Katarzyna Starowicz FIBROBLAST-LIKE SYNOVIOCYTES STIMULATED WITH TNFα
NO CANNABINOID RECEPTOR Rebecca M. Craft*, Stevie C. MEDIATION OF ANTINOCICEPTION Britch, Abby M. Pondelick P3-7 PRODUCED BY NON-STEROIDAL and Georgie A. Rosales ANTI-INFLAMMATORY DRUGS
EFFECTS OF Δ9-THC AND MONOACYLGLYCEROL LIPASE Clare Diester*, Matthew Banks INHIBITORS ON PAIN-STIMULATED P3-8 and S. Stevens Negus AND PAIN-DEPRESSED ACUTE PAIN BEHAVIORS IN MICE
Narendar Dudhipala*, Corinne INTRAOCULAR PRESSURE Sweeney, Ruchi Thakkar, Tabish LOWERING EFFICACY OF Mehraj, Sushruth Marathe, Δ9-TETRAHYDROCANNABINOL P3-9 Waseem Gul, Mahmoud A. VALINE HEMISUCCINATE LOADED ElSohly, Brian Murphy NANOEMULSION IN A NORMOTENSIVE and Soumyaji Majumdar RABBIT MODEL
DEVELOPMENT OF ENDOCANNABINOID Matthew Elmes*, Dale Deutsch, TRANSPORT INHIBITORS FOR THE P3-10 Iwao Ojima and Martin Kaczocha THERAPEUTIC TREATMENT OF PAIN
Adela García-Martín*, Sonia COMPARISON OF THE Burgaz, Carmen Navarrete, NEUROPROTECTIVE ACTIVITY OF Concepción García, Giovanni CANNABIGEROL DERIVATIVES IN P3-11 Appendino, Alain Rolland, HUNTINGTON’S AND PARKINSON’S Javier Fernández-Ruíz DISEASE MODELS and Eduardo Muñoz
BIOCHEMICAL AND ANALYTICAL Sandra Glasmacher* CHARACTERIZATION P3-12 and Jürg Gertsch OF PEPTIDE ENDOCANNABINOIDS
ANTINOCICEPTIVE EFFICACY Hannah Y. Gogulski*, Timothy OF VAPORIZED CANNABIS G. Freels, Ryan J. McLaughlin P3-13 EXTRACTS IN A RAT MODEL and Rebecca M. Craft OF INFLAMMATORY PAIN
Kelsey Guenther*, CONDITIONED GAPING PRODUCED BY Cassidy Wideman, Erin Rock, DELAYED, BUT NOT IMMEDIATE, P3-14 Cheryl Limebeer EXPOSURE TO COCAINE IN RATS and Linda Parker
Ozge Gunduz-Cinar*, Sarvar Oreizi-Esfahani, Emma Brockway, Gabrielle Pollack, OLEIC ACID SUPPLEMENTATION Yuhong Lin, Grzegorz P3-15 IN FEAR EXTINCTION Godlewski, Judith Harvey-White, Resat Cinar, George Kunos and Andrew Holmes
Shiran Udi, Liad Hinden*, OBESITY-INDUCED CHRONIC Majdoleen Ahmad, Rivka Hadar, KIDNEY DISEASE IS AMELIORATED BY Malliga R. Iyer, Resat Cinar, DUAL INHIBITION OF CANNABINOID-1 P3-16 Michal Herman-Edelsteinand RECEPTOR AND iNOS and Joseph Tam
Paula Morales, Dow P. Hurst, Linda M. Console-Bram, Pingwei THIENOPYRIMIDINE DERIVATIVES P3-17 Zhao, Nadine Jagerovic*, Mary E. AS GPR55 LIGANDS Abood and Patricia H. Reggio
Lindsey Jay*, Olivia Rivellini, INVESTIGATING THE STATUS OF THE Charles Zawatsky, Joshua Park, ENDOCANNABINOID/CB1R SYSTEM P3-18 Grzegorz Godlewski, Resat Cinar IN CHRONIC ALCOHOL-INDUCED and George Kunos LUNG INFLAMMATION
Lipin Ji*, Yingpeng Liu, Anisha Korde, Alex Ciesielski, Alex Straiker, Othman Benchama, RETRO ESTER AND AMIDE Amey Dhopeshwarkar, Simiao ENDOCANNABINOID ANALOGUES P3-19 Wu, Chandrashekhar Honrao, WITH RESISTANCE TO Fei Tong, Ngan Tran, Ken ENZYMATIC HYDROLYSIS Mackie, Laura Bohn, Alexandros Makriyannis and Spyros Nikas
GPR55 DELETION CAUSES Clare T Johnson* DECREASES IN CNS PROSTAGLANDINS P3-20 and Heather B Bradshaw AND INCREASES IN 2-AG AND RELATED LIPIDS
CHRONIC (E)-Β-CARYOPHYLLENE Przemysław Kac*, ADMINISTRATION IN RAT MODEL Jakub Mlost, Marta Bryk OF OSTEOARTHRITIS RESULTS IN CB2 P3-21 and Katarzyna Starowicz AND OPIOID RECEPTOR DEPENDENT ANALGESIC EFFECT
Andrew J. Kesner*, Matthew J. SLEEP DISTURBANCES IN Pava, Karina P. Abrahao MICE DURING CHRONIC THC P3-22 and David M. Lovinger ADMINISTRATION AND ABSTINENCE
PERIPHERAL CANNABINOID 1 RECEPTOR BLOCKADE IMPROVES INSULIN SENSITIVITY BY SUPPRESSING Wook Kim* P3-23 ADIPOSE TISSUE INFLAMMATION VIA NLRP3 INFLAMMASOME IN MOUSE MODELS OF OBESITY
C. Korn*, A. Osterwald, D. Holzer, E. Zirwes, K. Atz, B. Brennecke, E. M. Carreira, C. Davies, J. Fingerle, T. Gazzi, J. Gertsch, W. Guba, A. Kimbara, M. Maccarrone, H. Mandhair, R. E. Martin, A. Mason, T. Miljus, M. Nazare, M. Nettekoven, S. NOVEL AND HIGHLY SELECTIVE CB2R Oddi, P. Pacher, A. Pavlovic, A. FLUORESCENT PROBES FOR TRACING P3-24 Pedrina-McCarthy, P. Pfaff, C. CB2R-POSITIVE CELL POPULATIONS Raposo, M. Rogers-Evans, E. Roome, S. Röver, A. Rufer, R. Sarott, M. Soethoudt, M. van der Stelt, D. Sykes, Z. Varga, D. B. Veprintsev, M. Weise, M. Westphal, U. Grether and C. Ullmer
Alexis League*, Douglas Hermes, Clare Johnson, Megan Key, MONOACYLGLYCEROL Micah Niphakis, Benjamin LIPASE INHIBITOR MJN110 P3-25 Cravatt, Ken Mackie, Aron REDUCES HIV-1 TAT-INDUCED Lichtman, Bogna Ignatowska- EXCITOTOXICITY IN VITRO Jankowska and Sylvia Fitting
THC AND FENTANYL INTERACTION Timothy W. Lefever*, IN RATS: EVALUATION OF Jenny L. Wiley P3-26 RESPIRATORY EFFECTS AND and Herbert H. Seltzman ADVERSE HEALTH OBSERVATIONS
INTRAVITAL IMAGING Christian Lehmann*, OF INFLAMMATION AND Ian Burkovskiy P3-27 MICROCIRCULATION FOR and Juan Zhou CANNABINOID RESEARCH
ENDOCANNABINOID REGULATION OF Martin Leigh*, Malte Feja, CUE-INDUCED INCENTIVE MOTIVATION Ajay Baindur, Ken Wakabayashi, IN THE NUCLEUS ACCUMBENS P3-28 Micah Niphakis, Ben Cravatt AND VENTRAL TEGMENTAL and Caroline Bass AREA OF MALE RATS
Fouad Lemtiri-Chlieh, Tiwanna BDNF-INDUCED ENDOCANNABINOID M. Robinson, Jadin L. James RELEASE REGULATES SYNAPTIC P3-29 and Eric S. Levine* PLASTICITY
Erika Liktor-Busa*, ENHANCEMENT OF Beth M. Wiese, Kristen Kallen- ENDOCANNABINOID TONE Keck, Krishna Parsawar, P3-30 AS A NOVEL TARGET FOR Todd W. Vanderah TREATMENT OF MIGRAINE and Tally Largent-Milnes
Ziyi Liu*, Resat Cinar, Tony A DUAL-TARGET PERIPHERALLY Jourdan, Grzegorz Godlewski, RESTRICTED CB1R ANTAGONIST Malliga Iyer, Joshua Park, P3-31 PROMOTES PERIRENAL FAT BROWNING Keming Xiong, Jie Liu IN OBESE MICE VIA AMPK SIGNALING and George Kunos
Qing-Rong Liu*, Anna Canseco- MICROGLIA AND DOPAMINE Alba, Monika Chung, Brandon NEURON SPECIFIC CNR2 GENE Sanabria, Hai-Ying Zhang, KNOCKOUT MOUSE BRAINS SHOW P3-32 Zheng-Xiong Xi, Zhicheng Lin, CB2R BIASED INFLAMMATION Hiroki Ishiguro, Paritosh Ghosh SIGNALING PATHWAYS and Emmanuel Onaivi
TOPICAL MEDICAL CANNABIS-BASED MEDICINES: A NEW EPIGENETIC Vincent Maida* P3-33 PARADIGM FOR INTEGUMENTARY AND WOUND MANAGEMENT
INVESTIGATION OF THE EFFECTS OF Orlaith Mannion*, Emer Power, THE PERIPHERALLY RESTRICTED FAAH Hannah Casey, Brendan Harhen, INHIBITOR URB937 IN A RAT MODEL OF P3-34 Michael Scully, Brian E. McGuire POST-OPERATIVE PAIN FOLLOWING and David P. Finn INGUINAL HERNIA REPAIR SURGERY
NEURONAL PROPERTIES POST Jason Middleton*, TRAUMATIC BRAIN INJURY: Elizabeth Fucich, Zachary QUANTITATIVE COMPARISON, Stielper, Heather Cancienne, P3-35 CLASSIFICATION AND MODULATION Scott Edwards, Nicholas Gilpin BY CANNABINOID DEGRADATION and Patricia Molina ENZYME INHIBITORS
Tristen Mier*, Amanda Essex, Shawyon Baygani, John Hainline, ENDOCANNABINOID MACHINERY Tin Duong, Kylie Black, REGULATES CEREBELLAR GRANULE P3-36 Alexandria Bell, Ken Mackie CELL DEVELOPMENT and Anna Kalinovsky
Chanté A. Muller*, ENDOCANNABINOIDS AND Diane L. Lynch, Dow P. Hurst P3-37 THEIR ACTION AT TRPV1 and Patricia H. Reggio
Agnes Tatum-Kuri, Lorena Macías-Triana, Karen Romero- CHRONIC INJECTIONS OF WIN 55, 212-2 Cordero, Alba Vera-Barrón, IN YOUNG RATS CAUSE SLEEP P3-38 Gloria Arankowsky-Sandoval, DISTURBANCES IN ADULTHOOD Daniele Piomelli and Eric Murillo-Rodriguez*
Carmen Navarrete*, Adela García, Martin Garrido, EFFECTS OF EHP-101 ON Leyre Mestre, Miriam Mecha, INFLAMMATION AND REMYELINATION P3-39 Ana Feliú, Carmen Guaza, IN MURINE MODELS OF MULTIPLE Alain Rolland SCLEROSIS and Eduardo Muñoz
MAGL REGULATION OF EXCITATORY Alexis Papariello*, David Taylor, SYNAPSES IN ASD PATIENT IPSC P3-40 Ken Soderstrom and Karen Litwa DERIVED CORTICAL ORGANOIDS
Florent Pechereau*, Sébastien Lacroix, Nadine Leblanc, SMALL INTESTINE METABOLIC AND Alain Houde, Cyril Martin, ENDOCANNABINOIDE ADAPTATION IN P3-41 Nicolas Flamand, Cristoforo RESPONSE TO AN OBESOGENIC DIET Silvestri, Vincenzo Di Marzo and Alain Veilleux
Pedro A Perez*, PERIPHERAL CANNABINOID CB1 Donovan A Argueta RECEPTORS CONTROL NUTRIENT- P3-42 and Nicholas V DiPatrizio INDUCED INCRETIN SECRETION IN VIVO
Gavin Petrie*, Georgia Balsevich, TONIC ENDOCANNABINOID Tamas Fuzesi, David Rosenegger, SIGNALLING GATES STRESS-LIKE P3-43 Robert Aukema, Jaideep Bains STEREOTYPIC BEHAVIORS and Matthew Hill
THE ROLE OF THE CANNABINOID Samantha L. Pollock*, RECEPTORS IN THE EFFECTS OF Sara Rubovits P3-44 GABAPENTIN ON FORMALIN- and Cecilia J. Hillard INDUCED HYPERALGESIA
Julian Romero*, Noelia Aparicio, Diego Herraez, Maria Posada, FAAH-KO ASTROCYTES EXHIBIT Irene Benito-Cuesta, P3-45 A PRO-INFLAMMATORY PHENOTYPE Benjamin Cravatt, Teresa Grande and Rosa Tolon
THERAPEUTIC EFFECT OF Prabhuanand Selvaraj*, Jie Wen, THE SUBSTRATE-SELECTIVE Mikiei Tanaka, Scott Sackett CYCLOOXYGENASE-2 INHIBITION P3-46 and Yumin Zhang IN A MOUSE MODEL OF REPETITIVE CLOSED HEAD INJURY
Zachary Stielper*, TRAUMATIC BRAIN INJURY ALTERS Elizabeth Fucich, Garrett Sauber, THE ENDOCANNABINOID SYSTEM Cecilia Hillard, Scott Edwards, P3-47 IN THE BASOLATERAL AMYGDALA Patricia Molina OF FEMALE RATS and Nicholas Gilpin
IMPACT OF A PERIPHERALLY RESTRICTED CANNABINOID AGONIST Richard A. Slivicki* ON INFLAMMATION-INDUCED P3-48 and Robert W. Gereau IV NOCICEPTION AND TRPV1 SENSITIZATION IN DORSAL ROOT GANGLION NEURONS
POTENTIAL DEVELOPMENT OF NOVEL John Starkus, Chad Jansen, ANALGESICS THROUGH ACTIONS OF Lori Shimoda, Alexander Stokes, MINOR CANNABINOIDS TARGETING P3-49 Andrea Small-Howard* TRANSIENT RECEPTOR (TRP) and Helen Turner SUPERFAMILY MEMBERS TRPV1, TRPV2, TRPM8 AND TRPA1
John Starkus, Chad Jansen, Lori Shimoda, Mark Speck, Alexander J Stokes, TERPENE REGULATION OF TRPV1: P3-50 Joel Kawakami, POTENTIAL PAIN THERAPEUTICS Andrea Small-Howard* and Helen Turner
Noori Sotudeh*, Paula Morales, MECHANISM OF ACTIVATION Dow Hurst, Diane Lynch P3-51 OF GPR18 BY ITSELF and Patricia Reggio
ANTI-ARTHRITIC EFFECTS OF Floyd F. Steele*, Sara R. Nass ENDOCANNABINOID ENZYME P3-52 and Steven G. Kinsey INHIBITION IN A MOUSE MODEL OF INFLAMMATORY ARTHRITIS
EXPRESSION LEVEL INDEPENDENT Gergő Szanda*, Éva Wisniewski INHIBITION OF LEPTIN RECEPTOR P3-53 and Viktória Horváth EXPRESSION BY THE CANNABINOID TYPE-1 RECEPTOR (CB1R)
ANTI-INFLAMMATORY EFFECTS BY PHARMACOLOGICAL INHIBITION Mikiei Tanaka*, Kazuya Yagyu, OR KNOCKDOWN OF FATTY ACID P3-54 Scott Sachett and Yumin Zhang AMIDE HYDROLASE IN BV2 MICROGLIAL CELLS
Louise Topping*, ANALYSIS OF THE Felix Clanchy, Fiona McCann, ANTI-INFLAMMATORY AND Ruth Gallily, Marc Feldmann, P3-55 ANALGESIC EFFECTS OF Raphael Mechoulam CANNABIDIOL IN ARTHRITIS and Richard Williams
Yudisleydis Valdés*, DEVELOPMENT OF BENZOIMIDAZOLIC Hery Chung, Jaime Mella-Raipán, STRUCTURE INHIBITORS OF HUMAN P3-56 Mario Faúndez FATTY ACID AMIDE HYDROLASE and Carlos David Pessoa-Mahana ENZYME (h-FAAH)
Dana Vaughn*, Justyna Kulpa, THE CORRELATION OF ANANDAMIDE Lina Paulionis, Bill Milgram AND CORTISOL IN DOGS FOLLOWING P3-57 and Gary Landsberg AN ACUTE STRESSOR
Haley A. Vecchiarelli*, Vincent Chiang, Kaitlyn Tan, Min Qiao, INVESTIGATING THE RELATIONSHIP Catherine M. Keenan, Samantha BETWEEN INFLAMMATION AND L. Baglot, Robert J. Aukema, P3-58 ENDOCANNABINOIDS IN THE Gavin N. Petrie, Quentin J. AMYGDALA DURING COLITIS Pittman, Keith A. Sharkey and Matthew N. Hill
CANNABIS AS A COMPLEMENTARY PALLIATIVE CARE TREATMENT FOR MariaLuisa Vigano*, CANCER PATIENTS: EXPLORATORY Rihab Gamaoun, Popi Kasvis P3-59 ANALYSIS OF DATA FROM THE and Antonio Vigano CANNABIS PILOT PROJECT OF THE MCGILL UNIVERSITY HEALTH CENTRE
POTENTIAL IMPACT OF MEDICAL Rihab Gamaoun, Popi Kasvis, CANNABIS TREATMENT ON PAIN Maria-Fernanda Arboleda, CONTROL AMONG CANCER PATIENTS Gligorka Raskovic, P3-60 IN QUEBEC – CANADA: THE CANNABIS Filareti Patronidis PILOT PROJECT AT THE MCGILL and Antonio Vigano* UNIVERSITY HEALTH CENTRE
THE EFFECT OF MEDICAL CANNABIS Popi Kasvis, MariaLuisa Vigano ON APPETITE IN CANCER ANOREXIA: P3-61 and Antonio Vigano* POTENTIAL MECHANISM OF ACTION AND PRELIMINARY RESULTS
Brynna Webb*, Kylie Black, John Hainline, Athanasios Liodos, Jacob LaMar, ENDOCANNABINOID SIGNALING P3-62 Ricardo Martinez, AFFECTS PINCEAU STRUCTURE Tin Duong, Ken Mackie and Anna Kalinovsky
Brynna Webb*, Kylie Black, John Hainline, Athanasios Liodos, ENDOCANNABINOID SIGNALING Jacob LaMar, Alexandria Bell, P3-63 REGULATES CEREBELLAR BEHAVIORS Ken Mackie and Anna Kalinovsky
Beth M. Wiese*, Erika Liktor- THE ROLE OF CANNABINOID RECEPTOR Busa, Alexandros Makriyannis, MEDIATION OF OPIOID INDUCED P3-64 Tally M. Largent-Milnes RESPIRATORY DEPRESSION IN THE and Todd W. Vanderah PREBÖTZINGER COMPLEX
Charles Zawatsky*, Joshua Park, THE ROLE OF CANNABINOID Nathan Coffey, Lindsey Jay, RECEPTOR 1 (CB1R) IN ALVEOLAR Grzegorz Godlewski, TYPE-2 EPITHELIAL AND MYELOID P3-65 George Kunos CELLS IN EXPERIMENTAL LUNG and Resat Cinar FIBROSIS DEVELOPMENT
BIODISTRIBUTIONS AND Schuyler Pruyn, FUNCTIONS OF ENDOCANNABINOIDS Andrew Thurston ACROSS THE BLOOD BRAIN P3-66 and HaiAn Zheng* BARRIER UNDER NORMAL AND ISCHEMIC CONDITIONS
Notes: Presenting Author*
Plenary Speaker
Sunday, June 30, 2019 11:30 – 12:30
US CANNABIS POLICY: IMPLICATIONS FOR PUBLIC HEALTH
Susan R. B. Weiss, Ph.D.
Director Division of Extramural Research National Institute on Drug Abuse, Bethesda, MD, USA
Across the United States and the world, cannabis policies are changing rapidly, with public health impacts that cannot yet be foreseen based on the current state of our knowledge. Over the past decade, cannabis use has increased in young and older adults, and each year at least 4 million people in the U.S. meet diagnostic criteria for cannabis use disorder. The non-alignment of Federal and State laws creates obstacles for researchers, public health officials, and patients, as well as those in the cannabis industry. So does the fact that cannabis products vary widely in potency (i.e., tetrahydrocannabinol (THC) concentrations), constituents, and formulations. Edibles and concentrated THC products may pose particular health and safety risks; cannabidiol (CBD) products are now widely available to treat myriad conditions with little or no regulation. This presentation will highlight the emerging public health and safety data from U.S. states that have implemented medical or adult use marijuana laws, with a focus on the challenges of implementing policies to minimize harm. It will also summarize what we currently know and what we still need to know about the adverse effects of cannabis and cannabinoids, as well as their potential therapeutic effects, so that we can better identify research needs and opportunities. More research on the long-term impact of cannabis use, particularly in adolescents, pregnant women (and their offspring), and persons with mental illness is greatly needed, as these groups are potentially the most at risk for adverse outcomes. Also, despite the widespread use of “medical marijuana” and CBD products, the potential therapeutic uses of cannabis and its constituent compounds require a great deal more study. To do so will require continuing to address long- standing barriers to research. As data accumulate, it will be important to remain unbiased in the assessment of both cannabis’s harms and its benefits, so that the advancing science can most effectively inform policy and benefit the public health.
ICRS Lifetime Achievement Award
Sunday, June 30, 2019 13:30 – 14:30
CANNABINOID PHARMACOLOGY: MY FIRST HALF CENTURY
Roger Pertwee MA, DPhil, DSc, HonFBPhS
Institute of Medical Sciences University of Aberdeen, Aberdeen, Scotland, UK
My cannabinoid research began at Oxford University, England, in the late 1960s, not long after the structural elucidation and first synthesis by Raphael Mechoulam et al. of two notable phytocannabinoids: Δ9- tetrahydrocannabinol (THC) and cannabidiol.
The 1970s, 80s and 90s. In some of my initial research, I (1) contributed to the discovery in cannabis of the phytocannabinoid, tetrahydrocannabivarin, and to its initial pharmacological characterization, (2) developed the mouse ring test, an in vivo assay for measuring catalepsy induced, for example, by THC, and (3) discovered that THC lowers the thermoregulatory set point in mice, such that they still regulate their core temperatures, but at “sub-normal” levels.
After moving to Aberdeen University in 1974, I continued my cannabinoid research, for example by developing an “ex vivo” assay for “THC-like” drugs. This is performed with murine isolated vasa deferentia in which CB1 agonists can produce concentration-related reductions in the size of electrically-evoked smooth muscle contractions, reductions now known to result from CB1 receptor-mediated inhibition of the neuronal release of contractile transmitters. I used this assay in a project led by Raphael Mechoulam that began in the late 1980s, and was prompted by the then recent discovery of CB1 receptors. This project provided the first evidence (1) that the endogenous compound, anandamide, is a CB1 agonist and so an “endocannabinoid” and hence (2) for the existence of an “endocannabinoid system” of cannabinoid receptors and “endocannabinoids”.
In the early 1990s I also helped found the ICRS, and later in that decade, interacted with the UK Government, with Medical organizations, and with UK and US multiple sclerosis patients who were self-medicating with cannabis. This I did in a manner that helped to encourage new medicalization of cannabis-derived cannabinoids.
The 21st century In this century, research in my laboratory has, for example, contributed to the discovery and/or development of (1) a water soluble synthetic analogue of THC, O-1057, (2) an allosteric site on the CB1 receptor, and (3) novel synthetic compounds that behave as positive allosteric modulators (PAMs) of CB1 or CB2 receptors. These PAMs include two CB1 PAMs (GAT211 and GAT229) that collaborators have shown to possess therapeutic potential for relieving neuropathic pain or ocular glaucoma, and a CB2 PAM (EC-21a) that may, for example, have therapeutic potential for the treatment of blood cancer. My laboratory also recently helped to identify novel actions of the phytocannabinoids, cannabidiol, cannabidiolic acid, cannabigerol and tetrahydrocannabivarin, and of a stable synthetic analogue of cannabidiolic acid. These novel actions have revealed important potential therapeutic uses for most of these compounds.
In the more distant past, my laboratory also contributed to the pharmacological characterization of certain notable synthetic cannabinoids, including methanandamide, ACEA, ACPA, AM251, AM281, AM630 and HU- 308, that had been designed and synthesized in the laboratories of some fantastic collaborators. Indeed, throughout the last half century, my research has involved productive and “synergistic” collaborations with many great scientists, based, for example, in Israel, the UK, the USA, Canada, Australia, Italy, Spain, Germany, Poland, Mexico or Russia.
Plenary Speaker
Monday, July 1, 2019 11:30 – 12:30
THE NEUROBIOLOGY OF DRUG ADDICTION: FROM DRUG REWARD TO HYPERKATIFEIA TO NEGATIVE REINFORCEMENT
George Koob, Ph.D.
Director National Institute on Alcohol Abuse and Alcoholism Rockville, MD, USA
Addiction is a chronically relapsing disorder characterized by compulsive drug seeking that is hypothesized to derive from multiple sources of motivational dysregulation. Positive reinforcement, incentive salience and pathological habits derive from super activation of reward neurotransmitter systems in the basal ganglia and set up negative reinforcement during withdrawal. The construct of negative reinforcement, defined as drug taking that alleviates a negative emotional state (hypohedonia, dysphoria, anxiety, hyperalgesia, irritability, and sleep disturbances- all comprising the term “hyperkatifeia”), is an addition source of motivation for compulsive drug seeking in addiction. The hyper negative emotional state associated with addiction has been termed hyperkatifeia from the Greek “katifeia” for “dejection or sadness” and is created by abstinence in the withdrawal/negative affect and protracted abstinence in the preoccupation/anticipation stages of the addiction cycle. In animal models, repeated extended access to drugs of abuse results in negative emotion-like states reflected in increased reward thresholds, decreased pain thresholds, anxiety-like and dysphoric-like responses. Such negative emotional states that drive negative reinforcement are hypothesized to derive not only from “within system” dysregulation of key neurochemical circuits that mediate incentive-salience/reward systems (dopamine, opioid peptides) in the ventral striatum but also from the” between system” recruitment of brain stress systems (corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin, vasopressin, glucocorticoids and neuroimmune factors) in the extended amygdala. Excessive drug taking is also accompanied by deficits in executive function produced by neurocircuitry dysfunction in the medial prefrontal cortex that may facilitate the transition to compulsive-like responding and relapse. Thus, compelling evidence exists to argue that plasticity in the brain pain emotional systems is triggered by acute excessive drug intake, is sensitized during the development of compulsive drug taking with repeated withdrawal, persists into protracted abstinence, and contributes to the development and persistence of compulsive drug seeking.
Young Investigator Award Presentation
Monday, July 1, 2019 13:30 – 14:00
ANANDAMIDE, FAAH, STRESS AND ANXIETY: A TRANSLATIONAL JOURNEY
Matt Hill, Ph.D.
Associate Professor The Hotchkiss Brain Institute University of Calgary, Alberta, Canada
Endocannabinoid signalling has been well characterized as a modulator of the stress response, but divergent roles of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) have been identified. Work from our lab, and others, has found that in rodent models stress results in a rapid induction of FAAH activity, which results in an attenuation of apparent "tonic" signaling at the CB1 receptor. This loss of AEA signaling, particularly within the amygdala, appears to contribute to the generation of a stress response as inhibition of FAAH can reverse a multitude of neurobehavioral and endocrine responses to stress. The relevance of FAAH and AEA signaling in humans has also been examined by characterizing the impact of a gene variant in the FAAH gene (C385A) which results in a protein destabilization of FAAH and an elevation of AEA signaling. Consistent with the rodent data, carriers of the C385A allele of the FAAH gene exhibit reduced anxiety and fear, dampened responses to stress and blunted activation of the amygdala in response to threatening stimuli. More recently, we have begun to explore the impacts of pharmacological FAAH inhibition in humans to determine its impact on measures of fear and stress responsively as well. Together, these data provide a strong translational platform to indicate that AEA signaling may gate activation of the amygdala in response to stress and thus limit the generation of emotional states, such as fear and anxiety, and thus targeting FAAH may be a novel pharmacological approach to treating stress-related psychiatric disorders in humans.
Kang Tsou Memorial Speaker
Tuesday, July 2, 2019 12:00 – 13:00
VEGAS AND ULTRA-LSD: NEW CHEMICAL AND SYNTHETIC BIOLOGICAL TECHNOLOGIES
Bryan Roth, M.D., Ph.D.
Director NIMH Psychoactive Drug Screening Program Distinguished Professor, Department of Pharmacology UNC Chapel Hill, NC, USA
In this talk I will highlight two new technologies. VEGAS is a synthetic biology technology which provides a platform for the directed evolution of proteins towards defined molecular objectives. I will show how this technology enables the creation of synthetic transcription factors, engineered receptors and allosteric state-dependent nanobodies. Ultra-LSD is an approach which provides a platform for the discovery of novel chemical matter from ultra-large virtual chemical libraries (Lyu, Wang et al, Nature 2019 for example). Recent examples will be provided which illustrate the potential utilities and power of these approaches.
President’s Lecture
Wednesday, July 3, 2019 15:00 – 16:00
The Structures and Functions of the Cannabinoid Receptors
Alexandros Makriyannis, Ph.D.
George D. Behrakis Chair of Pharmaceutical Biotechnology Director, Center for Drug Discovery (CDD) Northeastern University, Boston, MA, USA
Although a number of cannabinoid analogs had been synthesized beginning in the 1960’s, the discovery of the first cannabinoid receptor (CB1) took several decades. This happened through the joint efforts of a number of laboratories, and it involved the use of photoaffinity labelling of radioligands and imaging. The need for obtaining structural information on both CB1 and CB2 to serve as templates in target-based discovery led to computational efforts based on mutational studies for receptor modeling. More extended structural work involving the use of covalent ligands, targeted mutations and proteomic approaches in our laboratory, under the designation of Ligand Assisted Protein Structure (LAPS), provided more detailed experimental data and identified helix 6 in both receptors as being a key site involved in their activation/deactivation, validating some of the earlier computational efforts.
An intensive effort involving Scripps, iHuman in Shanghai, and our laboratory, the Center for Drug Discovery led to the crystal structure of the CB1 receptor, first in its inactive form using a suitably designed antagonist for crystallization and subsequently in its activated form, using two irreversible agonists. This work provided detailed information on the binding motif of CB1 ligands. It also validated the concept of a double-toggle (HX6 – Hx3) mechanism of activation. These first two successes were followed by the very recent crystallization of the CB2 receptor, which provided some initial evidence for the complementarity of the two receptors and introduced the activation/deactivation (ying-yang) receptor concept, which now serves as a basis for the development of CB2 agonist/CB1 antagonist therapeutic medications.
The availability of detailed structural information of a number of CB1 and CB2 ligand complexes, coupled with data on ligand-receptor dynamics, opens the door for the design of cannabinergic drugs with greater structural and functional specificity. The work also allows us, retrospectively, to examine the functional basis and potential improvement of pharmacologically useful ligands of potential therapeutic value. These include neutral antagonists, megagonists, functionally selective ligands, and CB1 irreversible chemical knock-out antagonists.
Copyright © 2019 International Cannabinoid Research Society